996: Prevalence of germline MUTYH mutations among Lynch-like syndrome patients (Englisch)
- Neue Suche nach: Vargas, G.
- Neue Suche nach: Navarro, M.
- Neue Suche nach: Gonzalez, S.
- Neue Suche nach: Brunet, J.
- Neue Suche nach: Ramon y Cajal, T.
- Neue Suche nach: Balmana, J.
- Neue Suche nach: Lazaro, C.
- Neue Suche nach: Blanco, I.
- Neue Suche nach: Pineda, M.
- Neue Suche nach: Capella, G.
- Neue Suche nach: Vargas, G.
- Neue Suche nach: Navarro, M.
- Neue Suche nach: Gonzalez, S.
- Neue Suche nach: Brunet, J.
- Neue Suche nach: Ramon y Cajal, T.
- Neue Suche nach: Balmana, J.
- Neue Suche nach: Lazaro, C.
- Neue Suche nach: Blanco, I.
- Neue Suche nach: Pineda, M.
- Neue Suche nach: Capella, G.
In:
23rd Biennial Congress of the European Association for Cancer Research, 5-8 July 2014, Munich, Germany
;
S242
;
2014
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:996: Prevalence of germline MUTYH mutations among Lynch-like syndrome patients
-
Beteiligte:Vargas, G. ( Autor:in ) / Navarro, M. ( Autor:in ) / Gonzalez, S. ( Autor:in ) / Brunet, J. ( Autor:in ) / Ramon y Cajal, T. ( Autor:in ) / Balmana, J. ( Autor:in ) / Lazaro, C. ( Autor:in ) / Blanco, I. ( Autor:in ) / Pineda, M. ( Autor:in ) / Capella, G. ( Autor:in )
-
Erschienen in:EUROPEAN JOURNAL OF CANCER ; 50 ; S242
-
Verlag:
- Neue Suche nach: Elsevier Science B.V., Amsterdam.
-
Erscheinungsdatum:01.01.2014
-
Format / Umfang:S242
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 616.994
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 616.994 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 50
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 1.e1
-
EURECCA colorectal: Multidisciplinary management: European consensus conference colon & rectumvan de Velde, C. J. H. / Boelens, P. G. / Borras, J. M. / Coebergh, J. W. / Cervantes, A. / Blomqvist, L. / Beets-Tan, R. G. H. / van den Broek, C. B. M. / Brown, G. / Van Cutsem, E. et al. | 2014
- 3
-
1 Feasibility of large-scale genomic testing to facilitate enrollment on genomically-matched clinical trialsMeric-Bernstam, F. / Brusco, L. / Kopetz, S. / Davies, M. / Routbort, M.J. / Piha-Paul, S.A. / Alvarez, R. / Khose, S. / De Groot, J. et al. | 2014
- 7
-
3 Afuresertib (GSK2110183), an oral AKT kinase inhibitor, in combination with carboplatin and paclitaxel in recurrent ovarian cancerBlagden, S. / Hamilton, A. / Mileshkin, L. / Hall, M. / Meniawy, T. / Wong, S. / Anandra, S. / Buck, M. / McAleer, D. et al. | 2014
- 7
-
2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumorsPatnaik, A. / LoRusso, P. / Munster, P. / Tolcher, A.W. / Davis, S.L. / Heymach, J. / Ferraroto, R. / Xu, L. / Kapoun, A.M. et al. | 2014
- 8
-
5 Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinibSrinivasan, R. / Su, D. / Stamatakis, L. / Siddiqui, M.M. / Singer, E. / Shuch, B. / Nix, J. / Friend, J. / Hawks, G. et al. | 2014
- 8
-
6 Imaging in cancer immunology: Phenotyping of multiple immune cell subsets in-situ in FFPE tissue sectionsMansfield, J.R. / Slater, C. / Wang, C. / Roman, K. / Hoyt, C.C. / Byers, R.J. et al. | 2014
- 8
-
4 Activity of galeterone in castrate-resistant prostate cancer (CRPC) with C-terminal AR loss: Results from ARMOR2Taplin, M.E. / Chi, K.N. / Chu, F. / Cochran, J. / Edenfield, W.J. / Antonarakis, E.S. / Emmenegger, U. / Heath, E.I. / Hussain, A. et al. | 2014
- 9
-
7 Mouse clinical trial - A new preclinical study concept using patient-derived xenograftsVuaroqueaux, V. / Gredy, C. / Gorynia, S. / Baltes, S. / Fiebig, H.H. / Metz, T. et al. | 2014
- 9
-
9 Antineoplastic effects of auranofin in canine lymphomaThamm, D. / Rose, B.J. / Shoeneman, J.K. et al. | 2014
- 9
-
8 Imaging growth and anti-cancer activity in orthotopic patient derived tumorsBaugher, M. / Bull, C. / Cohen-Barnhouse, A. / Flecha, A. / Franklin, M. / Guley, K. / McConville, P. / Leopold, W.R. et al. | 2014
- 10
-
12 Next generation sequencing (NGS) guided therapy prediction for the treatment of glioblastoma multiforme (GBM)Sarkaria, J. / Ma, D.M. / Peng, S.P. / Byron, S.B. / Craig, D.C. / Carpten, J.C. / Berens, M.B. / O'Neill, B.O. / Tran, N.T. et al. | 2014
- 10
-
10 mTOR inhibition with everolimus - a novel treatment option for head and neck cancer identified in a translational research study using patient-derived xenograftsKlinghammer, K. / Raguse, J.D. / Plath, T. / Albers, A.E. / Brzezicha, B. / Wulf-Goldenberg, A. / Keilholz, U. / Hoffmann, J. / Fichtner, I. et al. | 2014
- 10
-
11 A panel of patient derived xenograft models of different haematological malignancies suitable for preclinical drug screening campaignsOswald, E. / Tschuch, C. / Klingner, K. / Hammerich, B. / Lehnhard, D. / Rentsch, C. / Lubbert, M. / Fiebig, H.H. / Schuler, J. et al. | 2014
- 11
-
14 Mixeno mouse models for in vivo evaluation of anti-human cancer immunotherapeuticsZhang, J. / Qiu, J. / Qiao, M. / Shi, Q. et al. | 2014
- 11
-
13 Whole exome sequence analysis of canine transitional cell carcinoma of the bladderDuval, D.L. / Hernandez, B. / Brown, J. / Lana, S.E. / Page, R. / Jones, K.L. et al. | 2014
- 11
-
15 Genetic and molecular validation of uterine sarcoma patient-derived xenograft modelsCuppens, T. / Hermans, E. / Depreeuw, J. / Moisse, M. / Van Brussel, T. / Coenegrachts, L. / Lambrechts, D. / Amant, F. et al. | 2014
- 11
-
16 Allografting improves the feasibility of genetically engineered mouse models (GEMM) for anti-cancer drug developmentKukuk, K. / Klingner, K. / Peille, A.L. / Muller, P. / Zipelius, A. / Schuler, J. et al. | 2014
- 12
-
18 Establishment and characterization of a Merkel Cell carcinoma PDX panel: Screening for potentially useful therapiesWick, M.J. / Meade, J. / Nehls, M. / Vaught, T. / Carlile, J. / Tolcher, A.W. / Rasco, D.W. / Patnaik, A. / Papadopoulos, K.P. et al. | 2014
- 12
-
17 Studies on glycoprotein expression differences between MCF-7 and MCF-7-ZNer-Kluza, J. / Drabik, A. / Kubbutat, M. / Lingnau, A. / Silberring, J. et al. | 2014
- 12
-
20 miR-25 is a key regulator of prostate cancer invasiveness by modulation of the cross-talk between Notch and TGF-@b signalingZoni, E. / van de Merbel, A.F. / van der Horst, G. / Rane, J. / Visakorpi, T. / Snaar, E.B. / Maitland, N. / van der Pluijm, G. et al. | 2014
- 12
-
19 Syngeneic models for developing cancer therapeutics targeting immune systemZhang, L. / Zhang, J. / Shi, Q. et al. | 2014
- 13
-
22 Novel combination therapy, TAS-102 combined with the anti-EGFR antibody or the anti-VEGF antibody showed therapeutic benefit toward colorectal cancer xenograftsIshida, K. / Sakamoto, K. / Tanaka, N. / Oguchi, K. / Yamamura, K. / Fujioka, A. / Nakagawa, F. / Matsuo, K. / Utsugi, T. et al. | 2014
- 13
-
21 Pharmacogenomics of mithramycin in thoracic malignanciesFigg, W. / Sissung, T.M. / Peer, C.J. / Schrump, D. et al. | 2014
- 13
-
23 Phase I study of lurbinectedin (PM01183) administered on days (D) 1 & 8 every 3 weeks (q3wk) in patients (pts) with solid tumorsRatain, M.J. / Gore, L. / Szyldergemajn, S. / Diamond, J. / Geary, D. / Fernandez-Teruel, C. / Soto-Matos, A. / Sharma, M. / Jimeno, A. et al. | 2014
- 14
-
26 NPD926, a small molecule inducer of reactive oxygen species, kills cancer cells via glutathione depletionKawamura, T. / Kondoh, Y. / Muroi, M. / Kawatani, M. / Osada, H. et al. | 2014
- 14
-
25 An ING1b-derived peptide that inhibits cancer cell viability and promotes apoptosisBoyko, A. / Riabowol, K. et al. | 2014
- 14
-
24 Androgen receptor (AR) expression in triple negative breast cancer (TNBC): results from a phase II neoadjuvant trial with carboplatin and eribulin mesylate in TNBC patientsSiziopikou, K. / Parini, V. / Kaklamani, V. et al. | 2014
- 15
-
27 TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancerOguchi, K. / Sakamoto, K. / Kazuno, H. / Ueno, H. / Ishida, K. / Yokogawa, T. / Yamamura, K. / Kitamura, R. / Matsuo, K. et al. | 2014
- 15
-
28 Characterization of the type of cell death induced by novel tambjamine analogs in lung cancerMartin, A.R. / Soto-Cerrato, V. / Manuel-Manresa, P. / Korrodi-Gregorio, L. / Quesada, R. / Perez-Tomas, R. et al. | 2014
- 15
-
29 TAS-114 is a novel dUTPaseDPD inhibitor, its DPD inhibition reduces capecitabine dosage but does not diminish therapeutic window in human tumor xenograftsYano, W. / Kazuno, H. / Yokogawa, T. / Sakamoto, K. / Yoshisue, K. / Wakasa, T. / Fukuoka, M. / Matsuo, K. / Noguchi, K. et al. | 2014
- 16
-
30 The fungal-derived cyclohexadepsipeptide Destruxin E exerts multifaceted anticancer and antiangiogenic activitiesDornetshuber-Fleiss, R. / Heffeter, P. / Mohr, T. / Hazemi, P. / Kryeziu, K. / Seger, C. / Berger, W. / Lemmens-Gruber, R. et al. | 2014
- 16
-
31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitorCarpinelli, P. / Ceruti, R. / Alzani, R. / Re, C. / Ballinari, D. / Cribioli, S. / Russo, M. / Degrassi, A. / Texido, G. et al. | 2014
- 16
-
33 Combining the long-acting topoisomerase 1-inhibitor etirinotecan pegol with the PARP inhibitor rucaparib to provide anti-tumor synergy without increased toxicityHoch, U. / Charych, D. et al. | 2014
- 16
-
32 Replication stress is a determinant of synergy between gemcitabine and Chk1 inhibitionKoh, S.B. / Courtin, A. / Boyce, R. / Boyle, B. / Richards, F.M. / Jodrell, D.I. et al. | 2014
- 17
-
36 Suppression of metastasis and improvement of drug distribution by eribulin mesylateOzawa, Y. / Okamoto, K. / Adachi, Y. / Asano, M. / Tabata, K. / Funahashi, Y. / Matsui, J. et al. | 2014
- 17
-
37 Effect of a microtubule-targeting drug on cell-cell contacts in bladder epithelial tumour cellsAnton-Aparicio, L.M. / Castosa, R. / Haz, M. / Blanco, M. / Rodriguez, M. / Valladares, M. / Figueroa, A. et al. | 2014
- 17
-
35 BRCA1 expression exploratory analysis in patients of the phase III trial of trabectedin vs. doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomasAracil, M. / Lardelli, P. / Nieto, A. / Galmarini, C.M. et al. | 2014
- 17
-
34 Phase I, dose-escalation study of the investigational drug D07001-F4, an oral formulation of gemcitabine HCl, in patients (pts) with advanced solid tumors or lymphomaLin, C. / Su, W. / Lee, J. / Hsu, C. / Cheng, A. / Ho, H. / Huang, C. / Hsueh, S. et al. | 2014
- 18
-
39 Phytochemical indole-3-carbinol synergizes strongly with fludarabine and induces p53-dependent and -independent cell death in chronic lymphocytic leukemia cells irrespective of their IGHV mutation state and treatment resistancesPerez-Chacon, G. / Martinez-Laperche, C. / Rebolleda, N. / Somovilla-Crespo, B. / Munoz-Calleja, C. / Buno, I. / Zapata, J.M. et al. | 2014
- 18
-
38 The indolyl-chalcone CDD-026 induces cancer cell death through targeting of STMN1 and mitotic catastropheWegiel, B. / Wang, Y. / Jernigan, F. / Sun, L. et al. | 2014
- 18
-
40 Selectivity and mechanism of action studies for Polo Box-targeted, non-ATP based inhibitors of PLK1Baxter, M. / Craig, S. / McInnes, C. / Wyatt, M.D. et al. | 2014
- 19
-
42 Interaction of SJG-136 with cognate sequences of oncogenic transcription factorsMantaj, J. / Jackson, P.J. / Thurston, D.E. / Rahman, K.M. et al. | 2014
- 19
-
41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage IIIIV non-small cell lung cancerNatale, R. / Socinski, M. / Hart, L. / Lipatov, O. / Spigel, D. / Gershenhorn, B. / Weiss, G. / Kazmi, S. / Karaseva, N. et al. | 2014
- 19
-
43 CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitorsHung, L. / Chen, Y. / Lin, H. / Tsai, M. / Hsieh, H. / Chang, J. / Chen, N. / Yang, S. / Chen, T. et al. | 2014
- 20
-
44 Metformin and its impact on gastric cancer patients survival after gastrectomyLee, C.K. / Jung, M.K. / Jung, I.K. / Heo, S.J. / An, J.Y. / Kim, H.I. / Chung, J.H. / Hyung, W.J. / Noh, S.H. et al. | 2014
- 20
-
46 Broad-spectrum preclinical combination activity of eribulin combined with various anticancer agents in human breast cancer, lung cancer, ovarian cancer, and melanoma xenograft modelsAsano, M. / Matsui, J. / Towle, M.J. / Wu, J. / McGonigle, S. / Uenaka, T. / Nomoto, K. / Littlefield, B.A. et al. | 2014
- 20
-
45 Early preclinical study of BO-2094 for treatment of human colon cancer, in combination with 5-fluorouracilSu, T.L. / Ou, T.H. / Wu, M.H. / Lin, Y.W. / Lee, T.C. et al. | 2014
- 20
-
47 Lurbinectedin (PM01183) specifically targets RNA Pol II for degradation via the proteasome pathway in a transcription and TC-NER dependent fashionSantamaria, G. / Martinez-Leal, J.F. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 21
-
48 Trabectedin and lurbinectedin are effective against leukemic cells derived from patients affected by chronic and juvenile myelomonocytic leukemiaRomano, M. / Galli, A. / Panini, N. / Paracchini, L. / Beltrame, L. / Bello, E. / Licandro, S.A. / Cattrini, C. / Tancredi, R. et al. | 2014
- 21
-
49 siRNA targeting of mitochondrial thymidine kinase 2 (TK2) sensitizes cancer cells to gemcitabine and increases mitochondrial toxicityDi Cresce, C. / Ferguson, P. / Figueredo, R. / Rytelewski, M. / Vareki, S.M. / Vincent, M.D. / Koropatnick, J. et al. | 2014
- 21
-
50 The effect of esomeprazole, a proton pump inhibitor, on the pharmacokinetics of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors or lymphomasZhou, X. / Nemunaitis, J. / Pant, S. / Bauer, T. / Lockhart, A. / Patel, M. / Zhang, B. / Kelly, V. / Ullmann, C.D. et al. | 2014
- 22
-
53 Adeno-associated virus (AAV) carrying diphtheria toxin a gene for pancreatic cancer therapyChen, M. / Ho, C.Y. / Teng, M. / Chen, H. et al. | 2014
- 22
-
51 Development of rational combination therapy strategies to optimize treatment for GPNMB expressing Her2+ and triple negative breast cancerRose, A. / Maric, G. / Annis, M.G. / Smith, H. / Muller, W.J. / Siegel, P.M. et al. | 2014
- 22
-
52 Platinum(IV) derivatives of oxaliplatin: Cellular effects and in vivo potencyGoschl, S. / Pichler, V. / Brynzak, E. / Heffeter, P. / Jungwirth, U. / Jakupec, M.A. / Berger, W. / Galanski, M. / Keppler, B.K. et al. | 2014
- 23
-
55 Low, frequent doses of PM060184 induce remarkable in vivo antitumor activityAviles, P. / Guillen, M.J. / Lopez-Casas, P.P. / Sarno, F. / Cataluna, O. / Nunez, P. / Cuevas, C. / Hidalgo, M. et al. | 2014
- 23
-
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000)Delbaldo, C. / Serin, D. / Mousseau, M. / Greget, S. / Audhuy, B. / Priou, F. / Berdah, J.F. / Teissier, E. / Laplaige, P. / Zelek, L. et al. | 2014
- 23
-
54 MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patientsBarault, L. / Amatu, A. / Bleeker, F.E. / Moutinho, C. / Cassingena, A. / Tosi, F. / Venesio, T. / Esteller, M. / Bardelli, A. et al. | 2014
- 23
-
56 Radiosensitizing effect of sodium metaarsenite in a metastatic brain tumor modelKang, W.Y. / Park, Y.M. / Kim, S.J. et al. | 2014
- 24
-
60 Sodium metaarsenite cytotoxic activity is associated with telomere length and many types of arsenic transporters in non-small cell lung cancerPark, Y.M. / Kim, S.J. et al. | 2014
- 24
-
58 Pipecolidepsin A, Stellatolide A and Irvalec: New cyclodepsipeptides of marine origin with antitumor activityMolina-Guijarro, J.M. / Moneo, V. / Martinez-Leal, J.F. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 24
-
59 Discovery of novel inhibitor of FOXO nuclear-cytoplasmic shuttling from natural products of marine originCorrea, F.J.C. / de Pedro, N. / Quesada, L.R. / Costales, D.O. / Tormo, J.R. / Martin, J. / Reyes, F. / Genilloud, O. / Vicente, F. et al. | 2014
- 24
-
57 Differential antitumor activity of trabectedin, lurbinectedin, Zalypsis and PM00128 against a panel of human cells deficient in transcription and NER factorsMoneo, V. / Avila, S. / Martinez, P. / de Castro, B. / Cascajares, S. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 25
-
63 Radium-223 dichloride - Efficacy and mode-of-action in a mouse model of prostate cancer bone metastasisSuominen, M.I. / Fagerlund, K.M. / Rissanen, J.P. / Konkol, Y. / Alhoniemi, E. / Mumberg, D. / Ziegelbauer, K. / Kaskonen, S.M. / Halleen, J.M. et al. | 2014
- 25
-
62 Antitumor and temozolomide-sensitizing effects of sodium metaarsenite in an orthotopic glioblastoma xenograft modelKang, W.Y. / Park, Y.M. / Kim, S.J. et al. | 2014
- 25
-
61 A panel of pediatric liver cancer patient-derived xenografts to improve stratification of children with hepatoblastomaFabre, M. / Nicolle, D. / Gorse, A. / Deas, O. / Mussini, C. / Brugieres, L. / Ghigna, M.R. / Fadel, E. / Galmiche-Rolland, L. et al. | 2014
- 26
-
65 Phase II drug metabolism UGT1A enzyme affects cellular response of colon cancer cells to antitumor triazoloacridinone C-1305 treatmentAugustin, E. / Bartusik, E. / Theus, A. / Borowa-Mazgaj, B. / Mazerska, Z. et al. | 2014
- 26
-
66 Clinical validity of new genetic biomarkers of irinotecan neutropenia: An independent replication studyInnocenti, F. / Ramirez, J. / Qiao, W. / de Graan, A.J. / Ratain, M.J. / van Schaik, R.H.N. / Mathijssen, R.H.J. / Rosner, G.L. / Crona, D.J. et al. | 2014
- 26
-
64 Nifuroxazide halogenic derivatives induce ROS-mediated apoptosis and display antitumor activity against metastatic melanomade Farias, C.F. / Massaoka, M.H. / Girola, N. / Figueiredo, C.R. / Azevedo, R.A. / Tavares, L.C. / Travassos, L.R. et al. | 2014
- 27
-
67 Cytotoxic response as a result of the cross-talk between UGT mediated metabolism and modulation of UGT activity by C-1311 and C-1305 acridinone antitumor agents in selected solid tumor cell linesMazerska, Z. / Pawlowska, M. / Bejrowska, A. / Szydlowska, M. / Fedejko, B. / Augustin, E. et al. | 2014
- 27
-
69 AKT3 activation mediates resistance to HER2-targeted therapies in HER2-amplified breast cancerSanz, F.C. / Montemurro, F. / Rossi, V. / Verma, C. / Berger, M. / Baselga, J. / Scaltriti, M. et al. | 2014
- 27
-
68 Can the P53 status predict the outcome of Polo-like kinase 1 inhibition in non-small cell lung cancer cell lines?Van den Bossche, J. / Wouters, A. / Deben, C. / Deschoolmeester, V. / Specenier, P. / Pauwels, P. / Peeters, M. / Lardon, F. et al. | 2014
- 28
-
72 Nrf2 as a molecular target in overwhelming chemoresistance in breast cancer therapySamadi, N. / Ramezani, F. / Sabzichi, M. et al. | 2014
- 28
-
70 Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRa-expressing cellsPan, J. / Shen, Y. / Ding, K. et al. | 2014
- 28
-
71 Novel regulation of estrogen receptor transcription by the PI3K pathwayToska, E. / Elkabets, M. / Bosch, A. / Litvin, O. / Scaltriti, M. / Baselga, J. et al. | 2014
- 28
-
73 Differential pathway resiliency in response to MAPK inhibition in BRAF-mutant cancerSos, M. / Levin, R.S. / Gordan, J.D. / Oses-Prieto, J.A. / Webber, J.T. / Salt, M. / Hann, B. / Burlingame, A.L. / McCormick, F. et al. | 2014
- 29
-
75 Loss of PTEN leads to acquired resistance to the PI3Ka inhibitor BYL719: a case of convergent evolution under selective therapeutic pressureCastel, P. / Juric, D. / Griffith, M. / Griffith, O.L. / Won, H.H. / Ainscough, B. / Ellis, H. / Ebbesen, S. / Gopakumar, I. et al. | 2014
- 29
-
74 Increased EDN1 expression mediates acquired resistance to the combination therapy of PI3K and MEK inhibitors for colorectal cancerBhattacharya, B. / Low, S.H.H. / Benoukraf, T. / Chong, M.L. / Koh, K.X. / Soong, R. et al. | 2014
- 29
-
76 Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitorsMarusiak, A.A. / Edwards, Z.C. / Hugo, W. / Trotter, E.W. / Girotti, M.R. / Stephenson, N.L. / Kong, X. / Gartside, M.G. / Fawdar, S. et al. | 2014
- 30
-
78 A comprehensive in vitro screen to identify therapeutic candidates for inclusion with etoposideplatin combinations to improve treatment of SCLCEvans, D. / Delosh, R. / Laudeman, J. / Ogle, C. / Reinhart, R. / Selby, M. / Silvers, T. / Monks, A. / Polley, E. et al. | 2014
- 30
-
77 Tumor suppressive roles of miR-221 and miR-222 in lung cancerSato, M. / Yamashita, R. / Kakumu, T. / Hase, T. / Maruyama, E. / Sekido, Y. / Kondo, M. / Hasegawa, Y. et al. | 2014
- 30
-
79 Quantitative proteomics as a tool to identify resistance mechanisms in erlotinib-resistant subclones of the non-small cell lung cancer cell line HCC827Jacobsen, K. / Lund, R.R. / Beck, H.C. / Ditzel, H.J. et al. | 2014
- 31
-
83 Acquired resistance to BET bromodomain inhibitors is associated with modulation of the apoptotic signaling networkSandy, P. / Nerle, S. / Conery, A. / Hatton, C. / Bryant, B. / Sims, R. / Normant, E. et al. | 2014
- 31
-
Impact of the transition from screen-film to digital screening mammography on interval cancer characteristics and treatment - A population based study from the NetherlandsNederend, J. / Duijm, L.E.M. / Louwman, M.W.J. / Coebergh, J.W. / Roumen, R.M.H. / Lohle, P.N. / Roukema, J.A. / Rutten, M.J.C.M. / van Steenbergen, L.N. / Ernst, M.F. et al. | 2014
- 31
-
81 Sensitization of triple-negative breast cancer to PI3K inhibition by cotargeting IGF1Rde Lint, K. / Poell, J.B. / Rodriguez, J.V. / Soueidan, H. / Nijkamp, W. / Wessels, L.F. / Beijersbergen, R.L. et al. | 2014
- 31
-
80 Determination of an oxidative stress gene signature in inflammatory breast cancer patient tumors and development of a novel redox modulatory strategy in overcoming chemotherapy resistance and mediating anti-tumor efficacyDevi, G.R. / Allensworth, J.L. / Evans, M. / Ueno, N. / McDonnell, D. / Bertucci, F. / Van Laere, S. et al. | 2014
- 31
-
82 Regorafenib resistance in colorectal carcinoma is associated with enhanced expression of type II interleukin 1 receptor and reversed by MEKERK inhibitorMar, A.C. / Chu, C.H. / Shiau, C.W. / Lee, T.C. et al. | 2014
- 32
-
86 Influence of EGFR exon 19 mutation subtypes on survival outcomes in advanced stage Asian non-small cell lung cancer patients receiving TKI therapyChowbay, B. / Singh, O. / Sutiman, N. / Tan, D.S.W. / Lim, W.T. / Tan, E.H. et al. | 2014
- 32
-
85 Wnt secretion is required to maintain Wnt activity in colon cancerVoloshanenko, O. / Erdmann, G. / Dubash, T.D. / Augustin, I. / Metzig, M. / Ball, C.R. / Glimm, H. / Spang, R. / Boutros, M. et al. | 2014
- 32
-
87 Critical difference in development of acquired resistance to MDM2 inhibitor SAR405838 in vitro and in vivoHoffman-Luca, G. / Yang, C.Y. / Lu, J. / Ziazadeh, D. / McEachern, D. / Debussche, L. / Wang, S. et al. | 2014
- 32
-
84 Src family kinase activation is a compensatory survival mechanism for acquired resistance to EGFR-TKIs in lung cancer cellsOno, M. / Sonoda, K. / Azuma, K. / Watari, K. / Molina, M. / Rosell, R. / Kuwano, M. et al. | 2014
- 33
-
90 Tumor infiltrating leukocyte subpopulations as a biomarker of response and resistance to targeted therapy in patients with BRAF mutation-positive metastatic melanomaKelley, M.C. / Doxie, D.B. / Greenplate, A.R. / Crandall, H. / Sosman, J.A. / Irish, J.M. et al. | 2014
- 33
-
89 Tie-2 regulates the stemness of prostate cancer cellsTang, K. / Ling, M. et al. | 2014
- 33
-
88 Genome-wide drug sensitivity screens in haploid mouse embryonic stem cellsPettitt, S.J. / Krastev, D. / Pemberton, H. / Fontebasso, Y. / Bajrami, I. / Kozarewa, I. / Frankum, J. / Rafiq, R. / Campbell, J. et al. | 2014
- 34
-
91 4E-BP1 expression levels determine sensitivity of triple negative breast cancer cells to mTOR inhibitorsJastrzebski, K. / Thijssen, B. / Rodriguez, J.V. / de Lint, K. / Lieftink, C. / Wessels, L.F. / Beijersbergen, R.L. et al. | 2014
- 34
-
93 A stress induced early innate response causes multi-drug tolerance in melanomaMenon, D.R. / Das, S. / Krepler, C. / Vultur, A. / Rinner, B. / Schauer, S. / Kashofer, K. / Wagner, K. / Zhang, G. et al. | 2014
- 34
-
92 Role of ERK nuclear translocation in cisplatin-sensitive and -resistant ovarian cancer cellsDilruba, S. / Kalayda, G.V. / Jaehde, U. et al. | 2014
- 35
-
96 Evaluation of hormone therapies in a panel of breast PDX models: Relevance of ER status on sensitivity to letrozole and tamoxifenWick, M.J. / Vaught, T. / Gamez, L. / Meade, J. / Diaz, A. / Papadopoulos, K.P. / Rasco, D.W. / Patnaik, A. / Beeram, M. et al. | 2014
- 35
-
97 Utilization of low passage adenoid cystic carcinoma PDX models to identify novel combination therapiesWick, M.J. / Meade, J. / Vaught, T. / Nehls, M. / Flores, J. / Kaufman, J. / Tolcher, A.W. / Rasco, D.W. / Patnaik, A. et al. | 2014
- 35
-
94 Elucidating mechanisms of resistance to FGFR inhibitors in endometrial cancerPacker, L. / Byron, S. / Mahon, C. / Loch, D. / Wortmann, A. / Nones, K. / Grimmond, S. / Pearson, J. / Waddell, N. et al. | 2014
- 35
-
95 Identification of synthetic lethality compounds from natural products for cancersNg, K.W. / Lee, K.S. / Patel, V. / Sundaramoorthy, E. / Ayoub, N. / Su, X. / Venkitaraman, A. / Teo, S.H. et al. | 2014
- 36
-
100 Small molecules selectively targeting breast cancer cellsSakoff, J. / Gilbert, J. / McCluskey, A. et al. | 2014
- 36
-
101 PIK3CA mutation-targeting compounds analyses using NCI60 cell line panelBando, H. / Lih, J. / Polley, E.C. / Holbeck, S.L. / Das, B. / Sims, D. / Doi, T. / Ohtsu, A. / Williams, M. et al. | 2014
- 36
-
99 Combination screening of investigational oncology agentsHolbeck, S. / Collins, J.M. / Doroshow, J.D. et al. | 2014
- 36
-
98 Synergistic inhibition of HER2 positive breast cancer by triptolide and lapatinibChalugun, P. / Shim, J.S. / Korangath, P. / Sukumar, S. / Liu, J.O. et al. | 2014
- 37
-
104 Identification of inhibitors of tryptophan metabolizing enzymes for cancer immunotherapy by high-throughput screeningZaman, G. / Uitdehaag, J.C.M. / van Gerwen, S. / Seegers, N. / van Doornmalen, A.M. / de Man, J. / Buijsman, R.C. et al. | 2014
- 37
-
103 The use of next generation sequencing (NGS) in the management of metastatic breast cancer (MBC): Defining a model for genomic-driven therapiesAustin, L. / Gooptu, M. / Avery, T. / Jaslow, R. / Palazzo, J. / Cristofanilli, M. et al. | 2014
- 37
-
102 Comparison of platinumtaxane and anthracycline-based therapies in ovarian PDX models: Correlating stage of biopsy collection and engrafting with in vivo drug sensitivityMeade, J. / Wick, M.J. / Vaught, T. / Gamez, L. / Farley, M. / Moriarty, A. / Tolcher, A.W. / Patnaik, A. / Rasco, D.W. et al. | 2014
- 38
-
105 A platform to test multiple therapy options simultaneously in a patient's own tumorCaffo, N. / Klinghoffer, R. et al. | 2014
- 38
-
107 CIGB-247: Anti-VEGF therapeutic vaccine in patients with advanced solid tumorsHernandez-Bernal, F. / Gavilondo, J.V. / Avila, M.A. / de la Torre, A.V. / de la Torre, J. / Selman-Housein, K.H. / Morera, Y. / Bequet-Romero, M. / Valenzuela, C.M. et al. | 2014
- 38
-
106 Beta-3 integrin inhibition reduces inflammatory cytokine release but not anti-cancer activity of oncolytic adenovirus in ovarian cancerBrowne, A.K. / Tookman, L.A. / Ingemarsdotter, C.K. / Bouwman, R. / Pirlo, K. / Wang, Y. / Hodivala-Dilke, K.M. / McNeish, I.A. / Lockley, M. et al. | 2014
- 39
-
110 IL-6STAT3Fra-1 signaling axis promotes colorectal cancer aggressiveness through epithelial-mesenchymal transitionShao, J. / Liu, H. et al. | 2014
- 39
-
111 Identification of peptides which could block PD-1 checkpoint for NSCLC immunotherapyZhu, Y. / Li, C. et al. | 2014
- 39
-
108 CD70 (TNFSF7), a receptor involved in acute immune modulation of viral infection, is frequently overexpressed in solid and hematological malignanciesJacobs, J. / Zwaenepoel, K. / Aftimos, P. / Rolfo, C. / Rottey, S. / de Lendonck, L.Y. / Silence, K. / Awada, A. / Thibault, A. et al. | 2014
- 39
-
109 Functional activity, but not PD-1 expression level, differentiates primary CLL from healthy PD1+ T cells using SCNPLiang, S. / Leung, L. / Putta, S. / Hotson, D. / Rosen, D. / Hawtin, R.E. et al. | 2014
- 40
-
115 Anti-metastatic activity via co-blockade of PD-1 and adenosine A2A receptorMittal, D. / Young, A. / Stannard, K. / Teng, M.W. / Allard, B. / Stagg, J. / Smyth, M.J. et al. | 2014
- 40
-
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancerLange, A. / Prenzler, A. / Frank, M. / Kirstein, M. / Vogel, A. / von der Schulenburg, J. M. et al. | 2014
- 40
-
112 A novel primary human tumor explant platform provides a preclinical translational link from tissue culture to the clinicJuan, G. / Paweletz, K. / Trueblood, E. / Rossi, J. / Damore, M. / Anderson, A. / Loberg, R. et al. | 2014
- 40
-
113 Preclinical activity and pharmacodynamic biomarkers of W014A, a PD-1 decoy peptide blocking both PD-1 immune checkpoint ligands, PD-L1 and PD-L2Bailly, C. / Broussas, M. / Ramachandra, M. / Sasikumar, P.G. / Shrimali, K. / Adurthi, S. / Satyam, L.K. / Dhudashia, A.A. et al. | 2014
- 40
-
114 Toll-like receptor 5 agonist entolimod as a potential anticancer immunotherapeutic agentBurdelya, L. / Brackett, C. / Kojouharov, B. / Veith, J. / Gudkov, A. et al. | 2014
- 41
-
116 Novel targets for antibody-drug conjugate therapyGrandi, A.G. / Campagnoli, S.C. / Parri, M.P. / de Camilli, E.D.C. / Jin, B.J. / Sarmientos, P.S. / Grandi, G.G. / Terracciano, L.T. / Pileri, P.P. et al. | 2014
- 41
-
117 ''Arming'' the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumoursChampion, B. / Kodialbail, P. / Illingworth, S. / Rasiah, N. / Cochrane, D. / Beadle, J. / Fisher, K. / Brown, A.C.N. et al. | 2014
- 41
-
118 Major synergy between Coxsackievirus A21 (CAVATAK(TM)) and radiotherapy or chemotherapy in bladder cancerSimpson, G.R. / Annels, N. / Ajaz, M. / Launchbury, F. / Bolton, G. / Melcher, A.A. / Harrington, K.J. / Au, G. / Shafren, D. et al. | 2014
- 42
-
120 Density of CD 8 +ve T cells & CD 56 +ve NK cells in follicular adenoma & papillary carcinoma of thyroid in Pakistani populationVarda, J. / Naseem, N. / Nagi, A.H. et al. | 2014
- 42
-
121 A modified double-deleted vaccinia virus combining viral oncolysis and potential gene therapy as a novel therapeutic for atypical teratoidrhabdoid tumorsRuan, Y. / Narendran, A. et al. | 2014
- 42
-
119 3-Bromopyruvate as an inducer of immunogenic cell death in colon cancer cellsJung, K.H. / Lee, J.H. / Park, J.W. / Quach, C. / Lee, K.H. et al. | 2014
- 43
-
123 Targeting tryptophan metabolism in human lung cancerDeshane, J. / Schafer, C. / Wang, Y. / Sawant, A. / Jin, T.H. / Zhi, D. / Ponnazhagan, S. / Grant, S. et al. | 2014
- 43
-
124 A WT1-derived peptide protects against metastatic melanoma in a syngeneic model by in vivo immunomodulatory effects on dendritic cellsMassaoka, M.H. / Figueiredo, C.R. / Girola, N. / Azevedo, R.A. / Travassos, L.R. et al. | 2014
- 43
-
122 Analysis of immune-response markers in resectable NSCLCUso, M. / Jantus-Lewintre, E. / Sirera, R. / Calabuig-Farinas, S. / Gallach, S. / Escorihuela, E. / Blasco, A. / Guijarro, R. / Camps, C. et al. | 2014
- 44
-
126 IMCgp100: A novel bi-specific biologic for the treatment of malignant melanomaShingler, W. / Harper, J. / Bossi, G. / Barker, D. / Dukes, J. / Liddy, N. / Paston, S. / Mahon, T. / Molloy, P. et al. | 2014
- 44
-
127 Correlation of clinical activity of pembrolizumab (MK-3475) with immunohistochemical staining for programmed death-1 ligand (PD-L1) in >=50% of tumor cells in a prospective non-small cell lung cancer (NSCLC) validation populationGaron, E.G. / Rizvi, N.A. / Leighl, N.B. / Hui, R. / Eder, J.P. / Patnaik, A. / Aggarwal, C. / Horn, L. / Balmanoukian, A.S. et al. | 2014
- 44
-
125 Critical issues in the clinical development of oncolytic viruses - A regulatory perspectiveSchuessler-Lenz, M. et al. | 2014
- 45
-
130 Preclinical results of ProCervix, a first in class, first in indication therapeutic vaccine targeting HPV1618 infected womenEsquerre, M. / Bouillette-Marussig, M. / Goubier, A. / Momot, M. / Keller, H. / Bissery, M. et al. | 2014
- 45
-
129 Characterization of PD-L1 expression in circulating tumor cells (CTCs) of non-small cell lung cancer (NSCLC) patientsKrupa, R. / Lu, D. / Harvey, M. / Louw, J. / Jendrisak, A. / Marrinucci, D. / Dittamore, R. et al. | 2014
- 45
-
128 T cell-mediated cancer immunotherapy through OX40 agonismHuseni, M. / Du, C. / Zhu, J. / Pacheco-Sanchez, P. / Moskalenko, M. / Chiu, H. / Dalpozzo, K. / Totpal, K. / Damico-Beyer, L. et al. | 2014
- 46
-
132 A novel anti-PDL1 antibody-based bifunctional protein with enhanced immunological activityWu, Y. / Martomo, S. / Zhong, Z. / Lu, D. / Polonskaya, Z. / Luna, X. / Zhang, Z. / Zhang, H. / Witte, L. et al. | 2014
- 46
-
133 Analysis of immune microenvironment in resectable NSCLC: Prognostic value of regulatory and conventional T cell markers proportionUso, M. / Sirera, R. / Calabuig-Farinas, S. / Blasco, A. / Pastor, E. / Guijarro, R. / Jantus-Lewintre, E. / Forteza, J. / Camps, C. et al. | 2014
- 46
-
131 Zfra activates novel Hyal2+ CD3- CD19- memory spleen cells to block cancer growth, stemness, and metastasis in vivoChang, N. et al. | 2014
- 47
-
136 Tumor-infiltrating lymphocytes (TILs) following intratumoral administration of ONCOS-102 are associated with prolonged overall survival in last line solid tumor patientsPesonen, S. / Joensuu, T. / Jager, E. / Karbach, J. / Wahle, C. / Kairemo, K. / Partanen, K. / Turkki, R. / Hemminki, A. et al. | 2014
- 47
-
134 Epigenetic immunomodulation by SGI-110 combined with immune checkpoint blockade for new therapeutic strategiesCovre, A. / Fazio, C. / Nicolay, H.J.M.G. / Natali, P.G. / Taverna, P. / Azab, M. / Coral, S. / Maio, M. et al. | 2014
- 47
-
135 AD-O64.3: IFN-@c-TRAIL fusion protein. Use of two independent signaling pathways for a strong synergistic antitumor effectZerek, B. / Pieczykolan, J.S. / Pawlak, S.D. / Rozga, P.K. / Pieczykolan, A. / Szymanik, M. / Jaworski, A. / Galazka, M. / Bukato, K. et al. | 2014
- 48
-
139 GBR1302: a BEAT(R) bispecific antibody for the treatment of HER2 positive cancersCroset, A. / Macoin, J. / Ollier, R. / Pluess, M. / Delon, C. / Skegro, D. / Blein, S. / Hou, S. / Back, J. et al. | 2014
- 48
-
140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)Daud, A. / Hamid, O. / Robert, C. / Hodi, F.S. / Wolchok, J.D. / Hwu, W.J. / Weber, J.S. / Kefford, R. / Hersey, P. et al. | 2014
- 48
-
138 Preclinical activity and safety of MGD006, a CD123xCD3 Bispecific DART(R) molecule for the treatment of hematological malignanciesMoore, P. / Chichili, G.R. / Huang, L. / Li, H. / Burke, S. / Chen, F. / He, L. / Tang, Q. / Jin, L. et al. | 2014
- 48
-
137 Immune checkpoint blockade enhances measles virotherapyEngeland, C.E. / Veinalde, R. / Grossardt, C. / Bossow, S. / Shevchenko, I. / Umansky, V. / Nettelbeck, D.M. / Jager, D. / von Kalle, C. et al. | 2014
- 49
-
142 IL-17 as a novel molecular target for prostate cancer preventionde Angulo, A. / Faris, R. / Jolly, C. / de Graffenried, L. et al. | 2014
- 49
-
141 Phase I study of ipilimumab with stereotactic radiosurgery for melanoma patients with brain metastasesShi, W. / Wuthrick, E. / Feeney, K. / Werner-Wasik, M. / Andrews, D.W. / Evans, J.J. / Judy, K. / Farrell, C. / Dicker, A.P. et al. | 2014
- 49
-
143 Regional bias of intratumoral genetic heterogeneity of nucleotide repeats in colon cancers with microsatellite instabilityAn, C. / Choi, Y. / Kim, M. / Lee, J. / Yoo, N. / Lee, S. et al. | 2014
- 50
-
145 ARQ 087, a novel pan FGFR-inhibitor crosses the BBB (blood-brain barrier) and distributes to the brain of ratsSavage, R. / Hall, T. / Schwartz, B. et al. | 2014
- 50
-
146 Establishment of patient-derived xenografts (PDX) models for triple negative breast cancer (TNBC) as a pre-clinical platform for drug developmentThatte, J. / Meza, M. / Ricono, J. / Broudy, T. / Mirsaidi, C. / Nair, P. et al. | 2014
- 50
-
Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown originThomassen, I. / Verhoeven, R.H.A. / van Gestel, Y.R.B.M. / van de Wouw, A.J. / Lemmens, V.E.P.P. / de Hingh, I.H.J.T. et al. | 2014
- 50
-
144 Association between interleukin 17interleukin 17 receptor gene polymorphism and papillary thyroid cancerEun, Y. / Chung, H. / Lee, Y.C. et al. | 2014
- 50
-
147 An integrated approach for identifying E-cadherin synthetic lethality networksBajrami, I. / Pettitt, S.J. / Brough, R. / Pemberton, H. / Kastrev, D. / Fontebasso, Y. / Frankum, J. / Campbell, J. / Ashworth, A. et al. | 2014
- 51
-
151 Impact of EGFR amplification pattern on the expression of miRNA-200c in primary glioblastoma multiformeHidalgo, L.M. / Gines, C.L. / Serna, E. / Monleon, D. / Callaghan, R. / Benso, R.G. / Martinetto, H. / Romero, A.G. / Darder, J.G. et al. | 2014
- 51
-
148 RAS synthetic lethal interactions from yeast to human cellsvan Wageningen, S. / Prahallad, A. / Heynen, G. / Rothstein, R. / Bernards, R. et al. | 2014
- 51
-
149 Quantitative mutational assessment of circulating tumor DNA using massively parallel deep sequencing in plasma and urine from advanced colorectal cancer patientsPoole, J.C. / Vibat, C.R.T. / Benesova, L. / Belsanova, B. / Hancock, S. / Lu, T.L. / Erlander, M.G. / Minarik, M. et al. | 2014
- 51
-
150 Pirin downregulates E-cadherin gene expression and contributes to EMTKomai, K. / Niwa, Y. / Sasazawa, Y. / Simizu, S. et al. | 2014
- 52
-
155 SNIPER(TACC3) degrades TACC3 protein via the ubiquitin-proteasome pathway and induces apoptosis in cancer cells expressing a large amount of TACC3Ohoka, N. / Nagai, K. / Okuhira, K. / Shibata, N. / Hattori, T. / Cho, N. / Naito, M. et al. | 2014
- 52
-
154 Drug response database with PDX tumor models in biomarker-driven multi-drug multi-arm clinical trial settingsJiang, J. / Yu, T.F. / Yan, Y. / Du, W. / Tan, T.T. / Hua, L. / Gu, J.L. / Yang, X.Q. / Liu, Z.H. et al. | 2014
- 52
-
153 Moving beyond in vitro models and addressing the challenges of pooled RNAi screens in mouse xenograftsTedesco, D. / Bonneau, K. / Makhanov, M. / Deng, D. / Sun, P. / Chenchik, A. et al. | 2014
- 52
-
152 Preclinical characterization of MM-151, an oligoclonal antibody therapeutic that targets EGFR by three distinct mechanisms of actionKing, A. / Sevecka, M. / Gerami-Moayed, N. / Burenkova, O. / Kearns, J. / Tan, G. / Sloss, C. / Bukhalid, R. / Nielsen, U. et al. | 2014
- 53
-
158 The development of a series of orthotopic solid tumour models of prostate, lung and ovarian cancer using optical and X ray imagingBatey, M. / Brown, M. / Bowden, E. et al. | 2014
- 53
-
159 Neoadjuvant chemotherapy in breast cancer patients induces expression of miR-34a and miR-122Freres, P. / Josse, C. / Bovy, N. / Boukerroucha, M. / Struman, I. / Bours, V. / Jerusalem, G. et al. | 2014
- 53
-
157 Sensitive and specific detection of 1p19q codeletion in gliomas by next generation sequencingDubbink, E. / Atmodimedjo, P.N. / van Marion, R.M. / Kros, J.M. / van den Bent, M.J. / Dinjens, W.N.M. et al. | 2014
- 53
-
156 Behaviour of platinum(IV) complexes with prodrug function in different models of hypoxiaBrynzak, E. / Heffeter, P. / Pichler, V. / Jakupec, M.A. / Keppler, B.K. et al. | 2014
- 54
-
161 Leveraging a novel DNA barcoding platform for integrated profiling and pharmacodynamic readoutsCastro, C. / Peterson, V. / Ullal, A. / Agasti, S. / Tuang, S. / Miller, N. / Birrer, M. / Weissleder, R. et al. | 2014
- 54
-
162 Drug-drug interaction predictions for MLN2480, an investigational pan-RAF inhibitor, based on nonclinical dataBalani, S.K. / Bulychev, A. / Cohen, L. / Liao, M. / Xia, C.Q. / Wang, F. / Li, P. / LeClair, B. / Bohnert, T. et al. | 2014
- 54
-
160 Identification of fusion genes through kinome-centered RNA sequencing in different types of solid tumorsMittempergher, L. / Sun, C. / Groenendijk, F.H. / Bosma, A.J. / Willems, S.M. / Sustic, T. / Majewski, I.J. / Grernrum, W. / Davidson, N.M. et al. | 2014
- 55
-
164 Augmentation of NAD+ by NQO1 activation attenuates cisplatin-mediated hearing impairmentYang, S. / Oh, G.S. / Kwon, K.B. / Park, R.K. / Lee, S.Y. / Moon, S.R. / So, H.S. et al. | 2014
- 55
-
165 Effect of zoledronic acid on the post-translational modification of activated leukocyte cell adhesion molecule (ALCAM) in cancer cellsToth, R. / Trombino, G. / Castronovo, V. / Bellahcene, A. et al. | 2014
- 55
-
166 Pre-clinical and clinical activity of Anti-DLL4 (demcizumab) in combination with gemcitabine plus nab-paclitaxel in pancreatic cancerHidalgo, M. / Cubillo, A. / Stagg, R. / Dupont, J. / Wan-Ching, Y. / Hoey, T. et al. | 2014
- 55
-
163 Interrogation of pharmacogenes in cancer patients using targeted DNA sequencingInnocenti, F. / Gillis, N. / Parker, J. / Hayes, N. / Eberhard, D. / Richards, K. / Auman, J.T. / Seiser, E. et al. | 2014
- 56
-
167 Genomic characterisation of 1003 cancer cell-linesBignall, G. / Iorio, F. / Futreal, P.A. / Stratton, M.R. / Campbell, P. / McDermott, U. et al. | 2014
- 56
-
168 CDCP1 as a new marker of aggressiveness in triple-negative breast cancersCampiglio, M. / Turdo, F. / Bianchi, F. / Sasso, M. / de Cecco, L. / Casalini, P. / Gasparini, P. / Forte, L. / Agresti, R. et al. | 2014
- 56
-
169 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics prototype platform (Idylla(TM))Janku, F. / Huang, H.J. / Claes, B. / Falchook, G.S. / Naing, A. / Piha-Paul, S. / Tsimberidou, A.M. / Zinner, R.G. / Karp, D.D. et al. | 2014
- 57
-
172 Modulation of estrogen-dependent transcription by cohesin in MCF7 human breast adenocarcinoma cellsDasgupta, T. / Antony, J. / Rhodes, J. / McEwan, M. / Eccles, M. / Horsfield, J. et al. | 2014
- 57
-
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancerLoupakis, F. / Cremolini, C. / Salvatore, L. / Masi, G. / Sensi, E. / Schirripa, M. / Michelucci, A. / Pfanner, E. / Brunetti, I. / Lupi, C. et al. | 2014
- 57
-
170 Novel, ultra-deep next-generation sequencing for BRAF mutation testing using small amount of cell-free DNA from plasma of patients with advanced cancersJanku, F. / Huang, H.J. / Ramzanali, N.M. / Cai, X. / Klausner, R. / Meric-Bernstam, F. / Fan, J.B. et al. | 2014
- 57
-
173 Ras-mediated activation of mitogen-activated protein kinase pathway unleashes basement membrane damaging activity of serine protease hepsinTervonen, T. / Pant, S. / Belitskin, D. / Englund, J. / Narhi, K. / Verschuren, E. / Kovanen, P. / Klefstrom, J. et al. | 2014
- 57
-
171 Antagonistic interaction between gemcitabine and erlotinib is influenced by EGR1 (early growth response 1) transcription factor expressionHose, C.D. / Zhao, Y. / Polley, E.C. / Fang, J. / Fer, N.D. / Rapisarda, A. / Teicher, B.A. / Simon, R.M. / Doroshow, J.D. et al. | 2014
- 58
-
175 Functional analysis of [methyl-^3H]choline uptake in glioblastoma cells: Influence of anti-cancer and central nervous system drugsInazu, M. / Taguchi, C. / Yamanaka, T. / Uchino, H. et al. | 2014
- 58
-
176 Resolvin D2 has mitogenic activity in estrogen receptor positive breast cancer cell lines via activation of estrogen receptorAl-Zaubai, N. / Johnstone, C. / Rizzacasa, M. / Stewart, A. et al. | 2014
- 58
-
174 Combination of molecular and drug response data in patient-derived xenografts to assist patient stratificationCairo, S. / Deas, O. / Beurdeley, A. / Yvonnet, V. / Poupon, M.F. / Judde, J.G. et al. | 2014
- 59
-
180 Identifying and monitoring somatic mutations in cell free DNA of patients with metastatic melanomaWisell, J. / Amato, C.M. / Robinson, W.A. et al. | 2014
- 59
-
177 Validation of 3D primary organoid cultures of colorectal carcinoma as discovery and validation platform for personalized cancer therapyHalonen, P. / Kuijpers, A. / Morris, B. / Diosdado, B. / Mainardi, S. / Bernards, R. / Verwaal, V. / Beijersbergen, R. et al. | 2014
- 59
-
178 Establishment of patient-derived xenografts (PDX) models for small cell lung (SCL) as a pre-clinical platform for drug developmentBroudy, T. / Ricono, J. / Mullins, C. / Mirsaidi, C. / Nair, P. et al. | 2014
- 59
-
179 Effects of human breast cancer cells secreted factors on macrophage differentiationde Sousa, S.C. / Brion, R. / Monkkonen, J. / Joensuu, H. / Heymann, D. / Maatta, J. et al. | 2014
- 60
-
182 TRAP1 represents a key mediator of stemness and glycolytic metabolism in colorectal cancer cellsLettini, G. / Maddalena, F. / Sisinni, L. / Condelli, V. / Del Vecchio, L. / Gemei, M. / Notarangelo, T. / Landriscina, M. et al. | 2014
- 60
-
181 Aberrant Wnt signaling activation in human cancers: In vitro and in vivo models to facilitate Wnt targeted drug developmentLiu, G. / Dong, C. / Zhang, R. / Zhang, L. / Qian, S. / Cai, J. / Zhang, J. / Ning, J. et al. | 2014
- 60
-
183 Spatio-temporal characterization of tumor growth and invasionJimenez, A.M. / Yogurtcu, O. / Horn-Lee, M. / Rao, P. / Sun, S.X. / Wirtz, D. et al. | 2014
- 60
-
185 Treatment of patient-derived NSCLC xenograft preclinical models using image-guided small animal irradiationPapadopoulou, N. / McKenzie, A. / King, J. / Page, M. / Kumari, R. et al. | 2014
- 60
-
184 Molecular profiling of heterogeneous tumor cellsChenchik, A. / Deng, D. / Bonneau, K. / Makhanov, M. / Coram, M. / Dolganov, G. / Jeffrey, S.S. et al. | 2014
- 61
-
188 RANBP2 knock-down is synthetic lethal with BRAF V600E in colon cancerVecchione, L. / Gambino, V. / d'Ario, G. / Tian, S. / Schlicker, A. / Mainardi, S. / Diosdado, B. / Simon, I. / Delorenzi, M. et al. | 2014
- 61
-
186 The use of Quantitative Textural Analysis imaging biomarkers to predict response to temsirolimus treatment in advanced HCC subjectsKorn, R. / Osarogiagbon, R. / Newbold, R. / Burkett, D. / Sachdev, J. et al. | 2014
- 61
-
187 Targeted genomic profiling of penile squamous cell carcinoma using the Oncomine cancer research panelMcDaniel, A.S. / Hovelson, D. / Cani, A. / Liu, C.J. / Zhang, Y. / Sadis, S. / Bandla, S. / Williams, P. / Rhodes, D. et al. | 2014
- 62
-
192 Extensive characterization of patient derived colon cancer xenografts for preclinical biomarker identificationVuaroqueaux, V. / Kiefer, F. / Bronsert, P. / Peille, A.L. / Zeitouni, B. / Foucault, F. / Kees, T. / Guo, J. / Schuler, J. et al. | 2014
- 62
-
189 Molecular and pharmacological characterization of primary mesothelioma tumor cell lines orthotopically xenografted in nude micePisano, C. / Cole, A. / Barbarino, A. / Bianchino, E. / Guglielmi, M. / Melito, C. / Mercadante, G. / Porciello, A. / Riccio, A. et al. | 2014
- 62
-
190 Differential chemosensitivity between CETCs and tumour spheroids in cancer patients with solid tumorsZimon, D. / Pizon, M. / Stein, E.L. / Pachmann, U. / Pachmann, K. et al. | 2014
- 62
-
191 Homotypic and heterotypic cell signaling transduction using a dielectrophoresis microfluidic deviceGabriel, M.T. / Heymann, D. et al. | 2014
- 63
-
193 The identification of new therapies for ependymoma subgroupsBoulos, N. / Dapper, J.D. / Patel, Y.T. / DeCuypere, M. / Bianski, B. / Mohankumar, K.M. / Jacus, M.O. / III, B.F. / Wright, K.D. et al. | 2014
- 63
-
194 Pancreatic ductal organoids as a new platform for drug discoveryPonz-Sarvise, M. / Corbo, V. / Ohlund, D. / Oni, T. / Handly-Santana, A. / Engle, D. / Tiriac, H. / Chio, C. / Feigin, M. et al. | 2014
- 63
-
195 A humanized mouse model for preclinical testing of molecules targeting immune checkpointsBaia, G. / Vasquez, D. / Ciznadija, D. / Sidransky, D. / Katz, A. / Paz, K. et al. | 2014
- 64
-
197 Statistical aspects of kinetic analysis of gliomas with FDG-PETHawe, D. / Hernandez, F.R. / Murphy, S. / Wolsztynski, E. / Huang, J. / O'Sullivan, J. / Muzi, M. / Eary, J. / Krohn, K. et al. | 2014
- 64
-
Small tumour size is associated with new-onset chronic kidney disease after radical nephrectomy in patients with renal cell carcinomaJeon, H. G. / Choo, S. H. / Sung, H. H. / Jeong, B. C. / Seo, S. I. / Jeon, S. S. / Choi, H. Y. / Lee, H. M. et al. | 2014
- 64
-
196 Neuropilin 2 (NRP2) modifies CXCL12CXCR4 signaling and promotes lymph node metastases in colon cancerSchneider, H. / Honscheid, P. / Scholch, S. / Jakob, C. / Muders, M. et al. | 2014
- 64
-
198 Genetic and pharmacological inhibition of PIM-1 reduces tumor development in a K-Ras-driven mouse model of non-small cell lung cancerAguirre, E. / Renner, O. / de Miguel, M.C.R. / Albarran, M.I. / Cebria, A. / Cebrian, D. / Ramos-Lima, F. / Pastor, J. / Blanco-Aparicio, C. et al. | 2014
- 65
-
199 Inhibitor of differentiation 1 (Id1) expression in lung cancer cells and liver microenvironment is required for liver metastasis (LM) development from non-small cell lung cancer (NSCLC) by regulating EMT-related and proliferation-related proteinsCastanon, E. / Soltermann, A. / Lopez, I. / Ecay, M. / Collantes, M. / Picazo, J.M.L. / Ponz, M. / Rolfo, C. / Calvo, A. et al. | 2014
- 65
-
202 The novel microtubule-destabilizing drug BAL101553 (prodrug of BAL27862) sensitizes a treatment refractory tumor model to ionizing radiationBroggini-Tenzer, A. / Bachmann, F. / Vuong, V. / Messikommer, A. / Nytko-Karouzakis, K. / O'Reilly, T. / Lane, H.A. / Pruschy, M.N. et al. | 2014
- 65
-
200 The influence of different cMET and EGFR backgrounds on the cytotoxicity of cMET and EGFR small molecule inhibitors in vitrovan der Steen, N. / Zwaenepoel, K. / Rolfo, C. / Giovannetti, E. / Castiglia, M. / Deschoolmeester, V. / Carreca, A.P. / Germonpre, P. / Pauwels, P. et al. | 2014
- 65
-
201 Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancerKim, S. / Park, S.H. / Lee, J. / Park, Y.S. / Kim, H.C. et al. | 2014
- 66
-
204 High-throughput functional screening identifies the flavoreductase POR as a principal determinant of sensitivity to the hypoxia-targeting prodrug SN30000Hunter, F.W. / Shalev, Z. / Wang, J. / Moffat, J. / Katella, T. / Koritzinsky, M. / Wilson, W.R. / Wouters, B.G. et al. | 2014
- 66
-
203 Ionizing radiation induced phosphatidylserine externalization on endothelial cell surface - a potential target for vascular targetingZhao, Z. / Johnson, M. / Chen, B. / Grace, M. / Ukath, J. / Lee, V. / Stoodley, M. et al. | 2014
- 67
-
206 Identification of novel targets for radiosensitisation of non-small cell lung cancer by secretome analysisSharma, A. / Bender, S. / Riesterer, O. / Broggini-Tenzer, A. / Pruschy, M. et al. | 2014
- 67
-
205 Metformin to modulate AMP-kinase and enhance chemotherapy and radiotherapy in non-small cell lung cancerTroncone, M.J. / Cargnelli, S.M. / Pond, G. / Tsiani, E. / Wright, J. / Steinberg, G. / Skinner, H. / Bo, L. / Bradley, J. et al. | 2014
- 67
-
207 The enhancement of radiotherapy efficacy with docetaxel-titanate nanotubes as a new nanohybrid for localized high risk prostate cancerMirjolet, C. / Boudon, J. / Loiseau, A. / Chevrier, S. / Gautier, T. / Boidot, R. / Paris, J. / Millot, N. / Crehange, G. et al. | 2014
- 68
-
208 Combined treatment of a DNA-PKcs inhibitor (NU7441) and ionizing radiation causes a differential mode of cell death in a panel of NSCLC cell lines and exhibits robust radiosensitisationSaha, D. / Lan, Y. / Hsu, F. / Tumati, V. / Zhang, Z. / Lin, Y. / Chen, B. et al. | 2014
- 70
-
Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trialAitchison, M. / Bray, C.A. / Van Poppel, H. / Sylvester, R. / Graham, J. / Innes, C. / McMahon, L. / Vasey, P.A. et al. | 2014
- 71
-
211 A novel synthetic lethal interaction between the histone mark H3K36me3 and checkpoint kinasesPfister, S.X. / Markkanen, E. / Jiang, Y. / Sarkar, S. / D'Angiolella, V. / Dianov, G. / Ryan, A.J. / Humphrey, T.C. et al. | 2014
- 71
-
210 A phase 1 study of KTN3379, a human anti-ErbB3 monoclonal antibody in patients with advanced cancersLoRusso, P. / LaVallee, T. / Kimmel, L. / Lubeski, C. / Gedrich, R. / Sidor, C. et al. | 2014
- 71
-
209 Pre-clinical and translational pharmacology, pharmacokinetics and pharmacodynamics for a humanized anti-OX40 antibody MOXR0916, a T-cell agonist in the treatment of solid tumorsSukumaran, S. / Kim, J.M. / Huseni, M. / Ruppel, J. / Taylor, H. / Totpal, K. / Zhu, J. / Zhang, C. / Chiu, H. et al. | 2014
- 72
-
212 Novel anti-tumor activity of targeted LSD1 inhibition by GSK2879552Mohammad, H. / Smitheman, K. / van Aller, G. / Cusan, M. / Kamat, S. / Liu, Y. / Johnson, N. / Hann, C. / Armstrong, S. et al. | 2014
- 72
-
213 A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumorsDoi, T. / Lin, C.C. / Ohtsu, A. / Yang, J.C.H. / Shitara, K. / Pronk, L.C. / Sarashina, A. / Cheng, A.L. et al. | 2014
- 72
-
214 Homologous recombination deficiency (HRD) score and niraparib efficacy in high grade ovarian cancerHaluska, P. / Timms, K.M. / AlHilli, M. / Wang, Y. / Hartman, A.M. / Jones, J. / Gutin, A. / Sangale, Z. / Neff, C. et al. | 2014
- 73
-
215 Updated clinical and preliminary correlative results of ARIEL2, a Phase 2 study to identify ovarian cancer patients likely to respond to rucaparibSwisher, E. / Brenton, J. / Kaufmann, S. / Oza, A. / Coleman, R.L. / O'Malley, D. / Konecny, G. / Ma, L. / Harrell, M. et al. | 2014
- 73
-
217 Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumour activity of AZD9150 in patients with advancedmetastatic hepatocellular carcinomaKang, Y.K. / Ryoo, B.Y. / Kim, T.Y. / Lee, K.H. / Lim, H.Y. / Lee, S.J. / Ikeda, M. / Okusaka, T. / Nadano, S. et al. | 2014
- 73
-
216 Phase I study of panobinostat and fractionated stereotactic re-irradiation therapy (FSRT) for recurrent high grade gliomasShi, W. / Lawrence, Y.R. / Werner-Wasik, M. / Andrews, D.W. / Evans, J.J. / Glass, J. / Kim, L. / Ad, V.B. / Moshel, Y. et al. | 2014
- 74
-
218 Genomic analysis identifies novel drivers and targetable pathways in inflammatory breast cancer patient samplesMoran, D.M. / Rao, K. / Bacon-Trusk, P. / Pry, K. / Weigman, V. / Velculescu, V. / Cristofanilli, M. / Bacus, S. et al. | 2014
- 74
-
220 Overcoming drug-resistance in multiple myeloma by XPO1 inhibitor combination therapyTurner, J. / Dawson, J. / Grant, S. / Shain, K. / Cubitt, C. / Dai, Y. / Zhoui, L. / Kauffman, M. / Shacham, S. et al. | 2014
- 74
-
219 Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients: A novel approach to treat HPV related malignancies?Deutsch, E. / Levy, A. / Mazeron, R. / Gazzah, A. / Angevin, E.A. / Ribrag, V. / Balheda, R. / Varga, A. / Lhomme, C. et al. | 2014
- 75
-
223 Preclinical assessment of nintedanib for chemoprevention in hepatocellular carcinomaTovar, V. / Moeini, A. / Torrecilla, S. / Higuera, M. / Peix, J. / Quetglas, I.M. / Rodriguez-Carunchio, L. / Cornella, H. / Sole, M. et al. | 2014
- 75
-
222 Estimating predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal tumor assaysDunn, B. / Steele, V.E. / Fagerstrom, R.M. / Topp, C.F. / Ransohoff, D. / Cunningham, C. / Lubet, R. / Ford, L.G. / Kramer, B.S. et al. | 2014
- 75
-
221 Docosahexaenoic acid along with modulation of actin binding proteins reduces cancer cell migrationAli, M. / Rogers, L.K. et al. | 2014
- 76
-
224 Synergic tumor growth suppression with carbohydrate-restriction diet and natural AMP-dependent protein kinase activatorsChoi, M. / Lee, J. et al. | 2014
- 76
-
225 Molecular targets of interest to the NCI PREVENT cancer preclinical drug development programShoemaker, R.H. / Dunn, B.K. / Suen, C. / Lubet, R.A. / Boring, D.L. / Klein, B.D. / Miller, M.S. / Steele, V.E. et al. | 2014
- 76
-
226 Efficacy of cancer preventing drugs administered by intermittent dosing regimensSteele, V.E. / Grubbs, C. / Rao, C.V. / Lubet, R.A. et al. | 2014
- 76
-
227 Multiplexed ICE COLD-PCR: A mutation detection methodology for achieving sensitivities of <0.01% using either Sanger or NGSWu, G. / Legendre, B. / Cherubin, S. / Cubrich, C. / Dowers, A. / Jensen, S. / Gniffke, J. / Kruempel, A. / Krzycki, P. et al. | 2014
- 77
-
229 DNA methyltransferase 1 expression in human solid tumors and lymphomas by immunohistochemistryYang, S.X. / Nguyen, D. / Rubinstein, L. / Kummar, S. / Tomaszewski, J.E. / Doroshow, J.H. et al. | 2014
- 77
-
228 Her2-3 heterodimer is a new and better than HER2 IHC score for clinical outcome prognosisWeitsman, G. / Barber, P.R. / Lawler, K. / Gillett, C. / Woodman, N. / Kholodenko, B. / Nguyen, L.K. / Santra, T. / Vojnovic, B. et al. | 2014
- 77
-
230 High correlation between clinical responses to first line AML patients treated with cytarabine and idarubicin and their pharmacological profiles in patient samples measured by ExviTechBallesteros, J. / Hernandez, P. / Primo, D. / Robles, A. / Espinosa, A.B. / Arroyo, E. / Garcia-Navas, V. / Sanchez-Fenoy, J. / Jimenez, M. et al. | 2014
- 78
-
Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abirateroneBianchini, D. / Lorente, D. / Rodriguez-Vida, A. / Omlin, A. / Pezaro, C. / Ferraldeschi, R. / Zivi, A. / Attard, G. / Chowdhury, S. / de Bono, J.S. et al. | 2014
- 78
-
233 Analytical validation and application of the MPACT assay, a next generation sequencing based targeted mutation detection assay for treatment selectionLih, C. / Sims, D.J. / Harrington, R.D. / Polley, E.C. / Zhao, Y. / Simon, R.M. / Mehaffey, M.G. / Forbes, T.D. / Walsh, W.D. et al. | 2014
- 78
-
231 Clinical pharmacodynamic assay development for the first in class investigational ubiquitin activating enzyme (UAE) inhibitor MLN7243Bahamon, B. / Gao, F. / Stringer, B. / Yang, Y. / Shi, J. / Burke, K. / Huck, J. / Traore, T. / Bowman, D. et al. | 2014
- 78
-
232 Development of a targeted NGS assay system for patient enrollment to the NCI-MATCH studyWilliams, M. / Sims, D. / Lih, J. / Datta, A. / Hamilton, S. / Iafrate, A.J. / Sklar, J. / Sadis, S. / Takabe, N. et al. | 2014
- 79
-
237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncologyBugano, D. / Hess, K. / Siu, L.L. / Meric-Bernstam, F. / Razak, A.R.A. / Hong, D.S. et al. | 2014
- 79
-
234 Kinetic analysis of dynamic ^1^1C-verapamil PET study: Compartmental v adaptive mixture models comparisonHernandez, F. / Hawe, D. / Murphy, S. / O'Sullivan, J. / Wolsztynski, E. / Huang, J. / Muzi, M. / Eary, J. / Krohn, K. et al. | 2014
- 79
-
235 Kinetic analysis of dynamic ^1^1C thymidine PET imaging studies: Compartmental and nonparametric approachesMurphy, S. / Hawe, D. / Hernandez, F. / Wolsztynski, E. / Huang, J. / O'Sullivan, J. / Muzi, M. / Eary, J. / Krohn, K. et al. | 2014
- 79
-
236 Whole genomic assay on endoscopic ultrasound-guided fine needle aspiration samples of unresectable pancreatic cancerHa, J.M. / Lee, K.H. / Lee, J.K. / Lee, K.T. / Park, W.Y. / Bae, J.S. / Jung, J.K. / Park, D.H. / Seong, Y.K. et al. | 2014
- 80
-
239 Niraparib, a selective PARP 12 inhibitor, is efficacious in pre-clinical models of small-cell lung cancerWang, Y. / Ricono, J. / Admunson, K. / Agarwal, S. / Fram, R.J. / Broudy, T. / Wilcoxen, K.M. et al. | 2014
- 80
-
238 Reversal of primary and acquired PARP-inhibitor resistance in BRCA-mutated triple-negative breast cancers by inhibition of transcriptional cyclin-dependent kinases (CDKs)Johnson, S. / Johnson, N. / Chi, D. / Primack, B. / Cruz, C. / Stover, D. / Greifenberg, A.K. / Cao, S. / O'Connor, K. et al. | 2014
- 81
-
241 Epigenetic loss-of-function BRCA1 mediates tumor cure by single dose radiotherapyCampagne, C. / Thin, T.H. / Fuller, J.D. / Manova-Todorova, K. / Haimovitz-Friedman, A. / Powell, S.N. / Kolesnick, R.N. / Fuks, Z. et al. | 2014
- 81
-
240 The combination of Chk-1 and ATR inhibitor synergistically kills cancer cellsSanjiv, K. / Hagenkort, A. / Reaper, P.M. / Koolmeister, T. / Mortusewicz, O. / Schultz, N. / Scobie, M. / Berglund, U.W. / Charlton, P.A. et al. | 2014
- 81
-
242 BMN 673 as single agent and in combination with temozolomide or PI3K pathway inhibitors in small cell lung cancer and gastric cancer modelsFeng, Y. / Post, L.E. / Cardnell, R. / Byers, L.A. / Wang, B. / Shen, Y. et al. | 2014
- 81
-
243 Modulation of PI3KmTOR pathway following PARP inhibition in small cell lung cancerCardnell, R.J. / Feng, Y. / Diao, L. / Fan, Y. / Masrorpour, F. / Mukherjee, S. / Shen, J. / Wang, J. / Byers, L.A. et al. | 2014
- 82
-
245 Chk1 is a potential novel therapeutic target that regulates cell survival and potentiates chemotherapy in osteosarcoma (OS) modelsStrauss, S.J. / Mistry, P. / Mendoza, A. / Robson, M. / Holme, H. / Nandabhiwat, P. / Kwok, B. / Qadir, M. / Pedley, R.B. et al. | 2014
- 82
-
244 Development of xenoimplants from germline BRCA12 mutant breast cancer (BC) for the identification of predictive biomarkers, mechanisms of resistance against poly(ADP-ribose) polymerase (PARP) inhibitors and evaluation of novel therapiesCruz, C. / Ibrahim, Y. / Morancho, B. / Anton, P. / Grueso, J. / Cozar, P. / GuzmAn, M. / Aviles, P.M. / Guillen, M.J. et al. | 2014
- 82
-
246 PARP inhibitors trap PARP1 onto damaged DNA via catalytic inhibition and not by an allosteric mechanismHopkins, T. / Solomon, L. / Shi, Y. / Rodriguez, L. / Donawho, C. / DiGiammarino, E. / Panchal, S. / Olson, A. / Stolarik, D. et al. | 2014
- 83
-
247 Selective inhibitors of nuclear export (SINE) block the expression of DNA damage repair proteins and sensitize cancer cells to DNA damage therapeutic agentsKashyap, T. / Crochiere, M. / Friedlander, S. / Klebanov, B. / Senapedis, W. / Baloglu, E. / del Alamo, D. / Tamir, S. / Rashal, T. et al. | 2014
- 83
-
248 Use of ATR inhibitor in combination with topoisomerase I inhibitor kills cancer cells by disabling DNA replication initiation and fork elongationJosse, R. / Martin, S.E. / Guha, R. / Ormanoglu, P. / Pfister, T. / Morris, J. / Doroshow, J. / Pommier, Y. et al. | 2014
- 83
-
249 Preclinical efficacy of the PARP inhibitor rucaparib (CO-338AG014699PF-01367338) in pancreatic cancer models with homologous recombination deficiencies (HRD)Robillard, L. / Lin, K. / Lopez-Casas, P.P. / Hidalgo, M. / Harding, T.C. et al. | 2014
- 84
-
251 A combined in vitro and mathematical modelling approach for understanding the impact of an inhibitor of ATR on DNA damage and repair after ionising radiationYates, J. / Checkley, S. / MacCallum, L. / Odedra, R. / Barnes, J. / Lau, A. et al. | 2014
- 84
-
252 The DNA damage response gene Schlafen 11 (SLFN11) is a transcriptional target of ETS transcription factors in Ewing's sarcoma and other cancersPommier, Y. / Bilke, S.W. / Sousa, F. / Yamade, M. / Murai, J. / Rajapakse, V. / Helman, L. / Meltzer, P. et al. | 2014
- 84
-
253 Phase 1 correlative study of ARQ761, a @b-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosisGerber, D. / Arriaga, Y. / Beg, M.S. / Dowell, J.E. / Schiller, J.H. / Frankel, A.E. / Leff, R. / Meek, C. / Bolluyt, J. et al. | 2014
- 84
-
250 Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genesChmielecki, J. / Hutchinson, K.E. / Frampton, G.M. / Chalmers, Z.R. / Johnson, A. / Shi, C. / Elvin, J. / Ali, S.M. / Ross, J.S. et al. | 2014
- 85
-
254 Molecular analysis in breast cancer: correlation with Immunohistochemical classification and pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC)Baulies, S. / Gonzalez-Cao, M. / Karachaliou, N. / Capitan, A.R. / Molina-Vila, M.A. / Cusido, M.T. / Teixido, C. / Viteri, S. / Fabregas, R. et al. | 2014
- 85
-
255 Pre-clinical in vivo characterization of MLN7243, an investigational ubiquitin activating enzyme inhibitor, in solid tumor modelsTraore, T. / Huck, J.H. / Shi, J.S. / Sappal, D.S. / Duffey, J.D. / Yang, Y.Y. / Kadakia, E.K. / Chakravarty, A.C. / Stringer, B.S. et al. | 2014
- 85
-
Chromosomal gains and losses in human papillomavirus-associated neoplasia of the lower genital tract - A systematic review and meta-analysisThomas, L. K. / Bermejo, J. L. / Vinokurova, S. / Jensen, K. / Bierkens, M. / Steenbergen, R. / Bergmann, M. / von Knebel Doeberitz, M. / Reuschenbach, M. et al. | 2014
- 85
-
256 Minicell packaged targeted delivery of shRNA to cancer cellsJivrajani, M. / Shrivastava, N. / Nivsarkar, M. et al. | 2014
- 86
-
258 Pancreatic cancer cells expressing the OATP1B3 transporter show promising sensitivity to the highly cytotoxic microcystin-LR moleculeKounnis, V. / Chondrogiannis, G. / Mantzaris, M.D. / Fokas, D. / Papanikolaou, N.A. / Sainis, I. / Briasoulis, E. et al. | 2014
- 86
-
259 Factors that limit delivery of Cdk46 inhibitor palbociclib to GBMParrish, K. / Pokorny, J. / Mittapalli, R. / Bakken, K. / Sarkaria, J. / Elmquist, W. et al. | 2014
- 86
-
257 Development of peptide-mediated drug delivery systems for colon cancer targeted imaging and therapyWu, H.C. / Wu, C.H. / Kuo, Y.H. et al. | 2014
- 87
-
261 Lesion characterization with ferumoxytol MRI in patients with advanced solid tumors and correlation with treatment response to MM-398, nanoliposomal irinotecan (nal-IRI)Ramanathan, R.K. / Korn, R.L. / Sachdev, J.C. / Fetterly, G.J. / Jameson, G. / Marceau, K. / Marsh, V. / Raghunand, N. / Prey, J. et al. | 2014
- 87
-
262 Improved cytotoxic activity of Nor-@b-lapachone-loaded PLGA microcapsules in PC3M prostate cancer cell linePessoa, C. / Feitosa, A.C.S. / Costa, M.P. / Evangelista, F.C. / Sales, F.A.M. / Bomfim, I.S. / Junior, E.N.S. / Dias, G.G. / Freire, V.N. et al. | 2014
- 87
-
263 Controlled release of cisplatin using hyaluronic oligosaccharides-coated gold nanoparticles as an efficient delivery system applied to the treatment of pancreatic tumorsParkkola, H. / Amieva, L.S. / Vivero, L. / Minana, R. / Sendra, J. et al. | 2014
- 87
-
260 Hsp90 Inhibitor Drug Conjugates (HDC): Payloads and possibilitiesChimmanamada, D. / Ying, W. / Zhang, J. / Proia, D. / Przewloka, T. / Jiang, J. / Vutukuri, D. / Lu, G. / Osman, S. et al. | 2014
- 88
-
264 Vasculogenic mimicry in small cell lung cancerTrapani, F. / Metcalf, R.L. / Polanski, R. / Fusi, A. / Hodgkinson, C. / Nonaka, D. / Hendrix, M.J. / Morrrow, C. / Blackhall, F. et al. | 2014
- 88
-
265 Pretargeted nanoparticles to deliver both chemotherapeutics and radiation for the treatment of lymphomaFang, C. / Jones, J.C. / Frayo, S.M. / Hylarides, M.H. / Zhang, M. / Press, O.W. et al. | 2014
- 89
-
267 Novel adjuvant therapy with leptin peptide receptor antagonist-2 conjugated to nanoparticles (IONP-LPrA2) to minimize chemoresistance in triple negative breast cancerHarmon, T. / Harbuzariu, A. / Yang, L. / Gonzalez-Perez, R.R. et al. | 2014
- 89
-
269 The NCI-60 as an effective tool for scaffold hopping: A phenotypic systems-based approach to the design of novel chemotherapeuticsWishka, D.G. / Kumar, V. / Teicher, B. / Kaur, G. / Fang, B. / Risbood, P. / Hollingshead, M. / Zais, J. / Morris, J. et al. | 2014
- 89
-
266 Auxiliar treatment by targeting the extracellular matrix to improve drug delivery and therapeutic responseHenke, E. / Roehrig, F. / Hoffmann, H. / Escorcia, F. / Wartenberg, M. / Volova, S. / Gaetzner, S. / Rosenwald, A. / Erguen, S. et al. | 2014
- 89
-
268 A potent and highly efficacious bivalent Smac Mimetic APG-1387 in Phase I clinical developmentLu, J. / Rong, S. / Sun, H. / Liu, L. / McEachern, D. / Wang, G. / Wen, J. / Zhai, Y. / Guo, M. et al. | 2014
- 90
-
272 8-(1-Anilino)ethyl)-2-morpholino-4-oxo-4H-chromene-6-carboxamides as PI3Kbetadelta inhibitors: structure-activity relationships and identification of AZD8186, a clinical candidate for the treatment of PTEN deficient tumoursBarlaam, B. / Cosulich, S. / Degorce, S. / Fitzek, M. / Green, S. / Hancox, U. / Lambert-van der Brempt, C. / Lohmann, J.J. / Maudet, M. et al. | 2014
- 90
-
271 Data integration and graph analysis for cancer genomics and drug discoveryBernard, B. / Miller, M. / Rovira, H. / Shmulevich, I. et al. | 2014
- 90
-
270 Discovery, development and optimization of low molecular weight EPH-ephrin protein-protein inhibitorsTognolini, M. / Giorgio, C. / Hassan-Mohamed, I. / Barocelli, E. / Mor, M. / Pala, D. / Russo, S. / Incerti, M. / Lodola, A. et al. | 2014
- 91
-
276 An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinonesAnil, B. / Blackburn, E. / Blackburn, T. / Cully, S. / Liu, J. / Drummond, C.J. / Endicott, J.A. / Golding, B.T. / Griffin, R.J. et al. | 2014
- 91
-
274 Novel cysteine derivatives for the next generation anticancer agents acting on KSPOgo, N. / Sawada, J. / Ishikawa, Y. / Matsuno, K. / Hashimoto, A. / Asai, A. et al. | 2014
- 91
-
275 Modulation of PIP2 levels through small molecule inhibition of PIP5KAndrews, D. / Cosulich, S. / Divecha, N. / Fitzgerald, D. / Flemington, V. / Jones, C. / Jones, D. / Kern, O. / MacDonald, E. et al. | 2014
- 91
-
273 Significance of serine-167 and cysteine-129 residues in the active site of the immune-suppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1) for the binding of novel inhibitorsTomek, P. / Palmer, B.D. / Flanagan, J.U. / Ching, L. et al. | 2014
- 92
-
278 Sentinel lymph nodes mapping of macrophage targeted mannosyl human serum albumin-indocyanine detected by combined color and near infrared fluorescence imaging system in esophagusQuan, Y. / Oh, Y. / Park, J.I.H.O. / Park, J. / Jeong, J. / Kim, B. / Kim, H. et al. | 2014
- 92
-
277 The discovery and pre-clinical development of the first clinical stage EZH2-inhibitor, EPZ-6438 (E7438)Kuntz, K. / Keilhack, H. / Pollock, R. / Knutson, S. / Warholic, N. / Richon, V. / Chesworth, R. / Copeland, R. / Porter-Scott, M. et al. | 2014
- 92
-
279 Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agentHsieh, H.P. / Kuo, C.C. / Chiu, J.J. / Hsu, T.A. / Yeh, T.K. / Chen, C.T. et al. | 2014
- 93
-
280 A hybrid drug design approach to overcome imatinib resistance for treating leukemiaWei, Y.M. / To, K.K.W. / Au-Yeung, S.C.F. et al. | 2014
- 93
-
282 Membrane anchorage of Stat3 via artificial protein lipidationAvadisian, M. / Fletcher, S. / Liu, B. / Zhao, W. / Turkson, J. / Gradinaru, C. / Gunning, P. et al. | 2014
- 93
-
281 Novel hybrid drug design strategy to circumvent erlotinib resistance and to optimize its pharmacokinetic properties for treating lung cancerPoon, D.C.S. / Au-Yeung, S.C.F. / To, K.K.W. et al. | 2014
- 94
-
285 A nanomolar-potency small molecule inhibitor of the STAT5 proteinCumaraswamy, A.A. / Lewis, A. / Geletu, M. / Todic, A. / Diaz, D.B. / Cheng, X.R. / Brown, C.E. / Laister, R. / Muench, D. et al. | 2014
- 94
-
283 The development of the first selective inhibitors of the UBA5 enzyme to probe for E1 activity in diseased cellsda Silva, S.R. / Paiva, S.L. / Bancerz, M. / Geletu, M. / Lewis, A.M. / Chen, J. / Cai, Y. / Li, H. / Gunning, P.T. et al. | 2014
- 94
-
284 Poly(ADP-ribose) glycohydrolase (PARG) inhibitors increase nuclear poly(ADP-ribose) after methylating DNA damageJordan, A. / Acton, B. / Fairweather, E. / Hamilton, N. / Holt, S. / Hitchin, J. / Hutton, C. / James, D. / Jones, S. et al. | 2014
- 95
-
286 Potent and selective non-sulfamate-containing small molecule inhibitors of the ubiquitin activating enzymePaiva, S. / da Silva, S.R. / Bancerz, M. / Quereshi, H. / Xu, G.W. / Schimmer, A.D. / Gunning, P.T. et al. | 2014
- 95
-
288 Synthetic isomalyngamide A analogs that inhibit breast cancer migrationLi, W. / Chang, T. / Hung, C. / Chen, C. / Jao, S. et al. | 2014
- 95
-
289 Progress in drugging CYP1A1, 1B1 and CYP2W1 overexpressed in cancerPors, K. / Le Morvan, V. / Travica, S. / Shnyder, S.D. / Sutherland, M. / Sheldrake, H.M. / Searcey, M. / Johansson, I. / Mkrtchian, S. et al. | 2014
- 95
-
287 The discovery and optimization of small molecule antagonists of the WDR5-MLL interactionAl-Awar, R. / Al-Awar, R.S. / Getlik, M. / Smil, D. / Bolshan, Y. / Poda, G. / Senisterra, G. / Wu, H. / Allali-Hassani, A. et al. | 2014
- 96
-
290 Exosome analysis in cancer patients: From the preclinical towards the clinical application: Trial designMertens, I. / Castiglia, M. / Carreca, A.P. / Baggertman, G. / Peeters, M. / Pauwels, P. / Rolfo, C. et al. | 2014
- 96
-
293 Inhibition of the cell cycle regulated Cdc7 kinase pathway is an efficacious therapeutic approach for hematologic malignancies and solid tumorsSantos, R. / Shum, D. / Carrillo, D. / Zhang, R. / Churchill, M. / Mukherjee, S. / Brentjens, R. / Radu, C. / Kelly, T.J. et al. | 2014
- 96
-
292 Salmonella typhimurium A1-R decoys quiescent cancer cells to cycle rendering them chemosensitiveYano, S. / Zhang, Y. / Zhao, M. / Hiroshima, Y. / Miwa, S. / Uehara, F. / Kishimoto, H. / Tazawa, H. / Fujiwara, T. et al. | 2014
- 96
-
291 Aflibercept has anti-tumor activity in bevacizumab-escaping tumors of colorectal cancer: Molecular profiles and mechanismsDib, C. / Bagley, R.G. / Mankoo, P. / Pollard, J. / Watters, J. / Chiron, M. et al. | 2014
- 97
-
294 Synthetic lethal screen identifies Aurora A as a selective target in HPV driven cervical cancerGabrielli, B. / Bokhari, F. / Ranall, M. / Stevenson, A. / Murell, M. / Kelly, M. / McKee, S. / Leggatt, G. / Gonda, T. et al. | 2014
- 97
-
296 A first-in-Asian phase I dose escalation study to evaluate the safety and pharmacokinetics of VS-6063 (defactinib), a focal adhesion kinase inhibitor in subjects with non-hematologic malignanciesShimizu, T. / Aida, H. / Horobin, J. / Keegan, M. / Padval, M. / Poli, A. / Hashii, C. / Nakagawa, K. et al. | 2014
- 97
-
295 Combining forces: Study of the cytotoxic effect of the MDM2 inhibitor Nutlin-3 in combination with CDDP in non-small cell lung cancer cell linesDeben, C. / Rolfo, C. / Deschoolmeester, V. / Wouters, A. / Peeters, M. / Gil-Bazo, I. / Lardon, F. / Pauwels, P. et al. | 2014
- 98
-
298 Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expressionKim, C. / Lee, B.S. / Kim, K.A. / Song, Y.J. / Cheong, K.H. et al. | 2014
- 98
-
299 Tyk2-src dependence of kidney cancerKrishnan, B. / Hanna, S.C. / Wilson, H.L. / Bailey, S.T. / Damrauer, J.S. / Simamura, T. / Levine, R.L. / Wong, K.K. / Johnson, G.L. et al. | 2014
- 98
-
297 Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLCChen, J. / Amato, K. / Wang, S. / Youngblood, V. / Brantley-Sieders, D. / Cook, R. / Tan, L. / Gray, N. et al. | 2014
- 98
-
300 Preclinical pharmacologic characterization of GSK2849330, a monoclonal AccretaMab(R) antibody with optimized ADCC and CDC activity directed against HER3Clarke, N. / Hopson, C. / Hahn, A. / Sully, K. / Germaschewski, F. / Yates, J. / Akinseye, C. / Mangatt, B. / Jonak, Z. et al. | 2014
- 99
-
301 Using PKPDefficacy modeling to predict potential of AZD9291 to target brain metastases from advanced NSCLC with EGFR sensitizing mutations (EGFRm+)Yates, J. / Ballard, P. / Ashton, S. / Cross, D. / Dattani, R. / Mellor, M. / Wilson, J. / Yang, P. / Xie, L. et al. | 2014
- 99
-
302 FAK inhibitor VS-6063 (defactinib) targets mesothelioma cancer stem cells which are enriched by standard of care chemotherapyPachter, J. / Kolev, V.N. / Baas, P. / Weaver, D.T. / Xu, Q. et al. | 2014
- 99
-
303 Genomic and epigenomic analysis identify potential therapeutic targets in luminal B breast cancer molecular subtypeKlouche, L.A. / Belhadj, A. / Bendaoud, A. / Benyelles, M. / Ziane, I. / Chaffanet, M. / Birnbaum, D. et al. | 2014
- 99
-
Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - A study of the OVCAD consortiumPils, D. / Bachmayr-Heyda, A. / Auer, K. / Svoboda, M. / Auner, V. / Hager, G. / Obermayr, E. / Reiner, A. / Reinthaller, A. / Speiser, P. et al. | 2014
- 100
-
304 PI3'-Kinase inhibition forestalls the development of drug resistance in BRAFV600EPTENNull melanomaDeuker, M. / Durban, V.M. / Phillips, W. / McMahon, M. et al. | 2014
- 100
-
306 CC-115 inhibits DNA damage and repair pathways in vitroTsuji, T. / Sapinoso, L. / Sankar, S. / Mortensen, D.S. / Xu, S. et al. | 2014
- 100
-
307 Stromal delivery of long Pentraxin-3 impairs FGFFGFR-dependent tumor growth and metastasisGiacomini, A. / Di Salle, E. / Coltrini, D. / Rezzola, S. / Belleri, M. / Presta, M. / Ronca, R. et al. | 2014
- 100
-
305 Selinexor, a novel selective inhibitor of nuclear export, potentiates the antitumor activity of gemcitabine against pancreatic cancer by nuclear retention of p27Amit, M. / Kazim, S. / Kazim, H. / Shacham, S. / Kauffman, M. / Malafa, M.P. et al. | 2014
- 101
-
310 Inhibition of Trk-driven tumors by the pan-Trk inhibitor RXDX-101Anderson, D. / Ciomei, M. / Banfi, P. / Cribioli, S. / Ardini, E. / Galvani, A. / Li, G. et al. | 2014
- 101
-
309 RNA sequencing and in silico analysis identifies an unannotated antisense long non-coding RNA involved in cancer progressionInoue, S. / Horie-Inoue, K. / Ikeda, K. et al. | 2014
- 101
-
311 IGF-1R inhibition induced activation of YesSFK acts as a by-pass resistance pathway in rhabdomyosarcomaWan, X. / Yeung, C. / Heske, C. / Mendoza, A. / Hlman, L.J. et al. | 2014
- 101
-
308 Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathwayGameiro, S. / Ardiani, A. / Kwilas, A.R. / Donahue, R.N. / Hodge, J.W. et al. | 2014
- 102
-
312 The prognostic role of mesothelin expression and its association with KRAS mutation in advanced lung adenocarcinomaThomas, A. / Chen, Y. / Steinberg, S. / Luo, J. / Giaccone, G. / Pastan, I. / Miettinen, M. / Hassan, R. et al. | 2014
- 102
-
313 Development of a one-step isolation platform for exosomal RNA and circulating cell-free DNA from cancer plasma samplesEnderle, D. / Brinkmann, K. / Koestler, T. / Bentink, S. / Berking, C. / Skog, J. / Noerholm, M. et al. | 2014
- 102
-
314 Optimal sequencing schedules for combining BRAF inhibition with BCL-2 inhibitionSchalck, A. / Frederick, D.T. / Hammond, M.R. / Ferreiro-Neira, I. / Cooper, Z.A. / Cusack, J.C. / Lawrence, D.P. / Flaherty, K.T. / Wargo, J.A. et al. | 2014
- 103
-
315 Biological characterization of TAS3681, a new type of androgen receptor antagonist with androgen receptor downregulating activityMinamiguchi, K. / Seki, M. / Aoyagi, H. / Mori, T. / Kajiwara, D. / Masuko, N. / Fujita, R. / Okajima, S. / Hayashi, Y. et al. | 2014
- 103
-
316 Potent, partial agonists at ERalpha as selective estrogen mimics for treatment of tamoxifen-resistant breast cancerThatcher, G. / Xiong, R. / Patel, H.K. / Zhao, J. / Liang, X. / Wang, Y. / Molloy, M.E. / Tonetti, D. et al. | 2014
- 103
-
318 Novel therapeutic targets for ARID1A mutant ovarian clear cell carcinoma (OCCC)Miller, R.E. / Bajrami, I. / Brough, R. / Konde, A. / Campbell, J. / Rafiq, R. / Ashworth, A. / Lord, C.J. et al. | 2014
- 103
-
317 IKK@b inhibition suppresses sphere formation and self-renewal of lung cancer initiating cellsCarneiro-Lobo, T. / Salviatto, A.C.P. / Baldwin, A.S. / Basseres, D.S. et al. | 2014
- 104
-
321 Potent and selective inhibition of EZH2 by AU-2121 leads to significant tumor growth inhibition in mutant EZH2 dependent non-Hodgkin lymphomaAhmed, S. / Narayanan, K. / Gadakh, A. / Dodheri, S. / Surendranath, S. / Nathan, S. / Mukherjee, S. / Marappan, S. / Sushmita, R. et al. | 2014
- 104
-
319 Genomic profiling of uterine leiomyosarcomas reveal frequent alterations in Aktmammalian target of rapamycin (mTOR) pathway genes and other actionable genomic abnormalities linked to targeted therapiesElvin, J.A. / Chalmers, Z.R. / Chiemlicki, J. / Wang, K.A.I. / Palma, N. / Ali, S.M. / Huho, A. / Sheehan, C.E. / Miller, V.A. et al. | 2014
- 104
-
320 First-in-human study with ARQ 092, a novel pan AKT-inhibitor, in subjects with advanced solid tumors or recurrent malignant lymphomaSaleh, M. / Papadpoulos, K. / Arabnia, A. / Patnaik, A. / Stein, R.M. / Chai, F. / Lamar, M. / Savage, R. / Abbadessa, G. et al. | 2014
- 105
-
322 Novel alternative splice variants as potential biomarkers and therapeutic targets in aggressive prostate cancer in men of African descentPatierno, S. / Freedman, J. / Wang, B. / Lee, N. / George, D. et al. | 2014
- 105
-
323 The development of short form of mimic microRNA for lung cancer therapyOhno, S. / Sudo, K. / Kuroda, M. et al. | 2014
- 105
-
324 Clinical pharmacokinetics (PK), translational PKpharmacodynamics (PD), and exposure-adverse events (AEs) relationship of MLN2480, an oral investigational pan-RAF kinase inhibitorZhou, X. / Olszanski, A.J. / Middleton, M. / Gonzalez, R. / Bargfrede, M.J. / Kneissl, M. / Bozon, V. / Gangolli, E. / Venkatakrishnan, K. et al. | 2014
- 106
-
327 Combination of MDM2 antagonists with RAS pathway inhibitors in colorectal cancerHiggins, B. / Tovar, C. / Kolinsky, K. / Zhang, Y. / Middleton, S.A. / Nichols, G. / Packman, K. / Su, F. / Vassilev, L. et al. | 2014
- 106
-
325 Identification and characterization of an irreversible inhibitor of CDK2Martin, M. / Anscombe, E. / Meschini, E. / Staunton, D. / Geitmann, M. / Danielson, U.H. / Wang, L.Z. / Vidal, R.M. / Reuillon, T. et al. | 2014
- 106
-
326 A novel non-ligand competing anti-EGFR antibody for cancer treatmentWang, X. / Rust, S. / Comer, F. / Muniz-Medina, V. / Du, Q. / Yuan, A. / Senthil, K. / Fleming, R. / Minter, R. et al. | 2014
- 106
-
328 Jagged1 expression and its relevance in metastatic progression of breast cancersBednarz-Knoll, N. / Efstathiou, A. / Gotzhein, F. / Wilkman, H. / Mueller, V. / Kang, Y. / Pantel, K. et al. | 2014
- 107
-
329 A first-in-human study evaluating the safety and pharmacology of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumorsBeeram, M. / Lieu, C. / Harb, W. / Power, L. / Kearns, J. / Nering, R. / Moyo, V. / Wolf, B. / Adjei, A. et al. | 2014
- 107
-
331 Biomarker discovery and validation for assessing the response to cMet inhibition and functional inactivationJung, S. / Selzer, S. / Lo@bner, C. / Kuhn, K. / Fiedler, U. / KlotzbUcher, A. / Zucht, H.D. / Koncarevic, S. / Prinz, T. et al. | 2014
- 107
-
330 Preclinical development of BIS-1602, first in class growth hormone releasing hormone antagonistMaxuitenko, Y.Y. / Block, N.L. / Schally, A.V. / Reich, S.J. / Goldstein, P. et al. | 2014
- 108
-
334 Aplidin: first in class compound targeting EEF1A in tumor cellsLosada, A. / Martinez, J.F. / Moral, P. / Carrasco, L. / Gago, F. / Cuevas, C. / Garcia-Fernandez, L.F. / Galmarini, C.M. et al. | 2014
- 108
-
333 Short antisense oligonucleotides antagonize Lin28 and enable pre-let-7 processing and suppression of cell growth in human hepatocarcinoma cellsRoos, M. / Civenni, G. / Lucic, M. / Pavlicek, D. / Pradere, U. / Towbin, H. / Catapano, C.V. / Hall, J. et al. | 2014
- 108
-
332 Dual PI3K deltagamma inhibition by RP6530 accentuates bortezomib activity in multiple myeloma cell linesViswanadha, S. / Babu, G. / Veeraraghavan, S. / Vakkalanka, S. et al. | 2014
- 108
-
335 RICTOR amplification as a novel molecular target for the treatment of lung cancerCheng, H. / Piperdi, B. / Zou, Y. / Verma, A. / Liu, X. / Schwartz, E. / Zhu, C. / Montagna, C. / Halmos, B. et al. | 2014
- 109
-
338 BM-1252 (APG-1252): a potent dual specific Bcl-2Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicityBai, L. / Chen, J. / Liu, L. / McEachern, D. / Aguilar, A. / Zhou, H. / Yang, C.Y. / Wang, H. / Wen, J. et al. | 2014
- 109
-
337 Sensitisation of HPV+ HNSCC to cytotoxic treatments by targeting the G2M checkpoint with AZ-1775 to improve survivalOsman, A. / Tanaka, N. / Patel, A. / Wang, J. / Fitzgerald, A. / Xie, T. / Zhao, M. / Jasser, S. / Gadhikar, M. et al. | 2014
- 109
-
336 The effect of food on the pharmacokinetics of the investigational Aurora A kinase (AAK) inhibitor, alisertib (MLN8237), in patients (pts) with advanced solid tumors or lymphomasZhou, X. / Bauer, T.M. / Goel, S. / Sarantopoulos, J. / Zhang, B. / Kelly, V. / Mertz, J. / Venkatakrishnan, K. et al. | 2014
- 110
-
341 Dinaciclib alters cell cycle dynamics and induces cell death in Soft Tissue SarcomasMargalef, N.M. / Rello-Varona, S. / Garcia-Monclus, S. / Fuentes-Guirado, M. / Tirado, O.M. / del Muro, X.G. et al. | 2014
- 110
-
340 Preclinical activity of the VEGFR, FGFR and PDGFR inhibitor lucitanib in FGFR2 aberrant endometrial and gastric cancer modelsGuffanti, F. / Chila, R. / Bello, E. / Ceriani, L. / Zangarini, M. / Zucchetti, M. / Saba, C. / Jacquet-Bescond, A. / Pierrat, M. et al. | 2014
- 110
-
339 NAMPT inhibition as strategy to impair tumor growthCerezo, A. / Jimenez, S. / Lospitao, E. / Bravo, N. / Campos-Olivas, R. / Aguilera, C. / Canamero, M. / Gilmour, R. / Geeganage, S. et al. | 2014
- 111
-
344 Search for new blood biomarkers for response to antiangiogenic therapy in non-small cell lung cancer patientsRodriguez-Garzotto, A. / Agullo-Ortuno, M.T. / Ponce, S. / Diaz-Garcla, C.V. / Agudo-Lopez, A. / Perez, C. / Prieto-Garcia, E. / Cortes-Funes, H. / Iglesias, L. et al. | 2014
- 111
-
342 A phase 12 study evaluating the safety, pharmacokinetics and efficacy of ABT-414 in subjects with advanced solid tumors likely to over-express the epidermal growth factor receptor (EGFR)Tolcher, A. / Goss, G. / Gordon, M. / Gandhi, L. / Papadopoulos, K.P. / Rasco, D. / Pedersen, M. / Fischer, J. / Ames, W. et al. | 2014
- 111
-
343 Salmonella typhimurium A1-R effectively targets experimental breast cancer brain metastasisZhang, Y. / Miwa, S. / Zhang, N. / Hoffman, R.M. / Zhao, M. et al. | 2014
- 111
-
The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patientsvan der Ploeg, A. P. T. / van Akkooi, A. C. J. / Haydu, L. E. / Scolyer, R. A. / Murali, R. / Verhoef, C. / Thompson, J. F. / Eggermont, A. M. M. et al. | 2014
- 111
-
345 Interaction of plitidepsin with eEF1A in living tumor cellsGarcia, C. / Losada, A. / Molina-Guijarro, J.M. / Sacristan, M.A. / Martinez, J. / Galmarini, C.M. / Lillo, M.P. et al. | 2014
- 112
-
348 Two NSCLC-PDXs with different EGFR exon 20-insertions respond differently to different TKIsLi, H. / Yang, M. / Cai, J. et al. | 2014
- 112
-
346 Inhibition of Wnt pathway by novel thiazole-based Traf2- and Nck-interacting kinase (TNIK) inhibitorUno, Y. / Moriyama, H. / Kashimoto, S. / Masuda, M. / Sawa, M. / Yamada, T. et al. | 2014
- 112
-
347 Can a link between the EGFR and cMET pathway in non-small cell lung cancer explain resistance against targeted therapies and open new therapeutic opportunities?van der Steen, N. / van der Steen, K. / Zwaenepoel, K. / Giovannetti, E. / Castiglia, M. / Carreca, A.P. / Pauwels, P. / Rolfo, C. et al. | 2014
- 113
-
349 Synergistic drug combinations that target beta-catenin-driven and MYC-driven cancersUitdehaag, J.C.M. / Spijkers-Hagelstein, J.A.P. / de Roos, J.A.D.M. / van Doornmalen, A.M. / Prinsen, M.B.W. / de Man, J. / Buijsman, R.C. / Zaman, G.J.R. et al. | 2014
- 113
-
350 Oncogenic Ras mutants differentially utilize PLC-dependent calcium flux and PKC activation for MAPK signalingPitt, C. / McCormick, F. et al. | 2014
- 113
-
351 hz515H7, a humanized antibody exerts its antitumor activity via antagonism of the CXCR4SDF-1 axis, and through effector functionsKlinguer-Hamour, C. / Broussas, M. / Akla, B. / Berger, S. / Boute, N. / Beau-Larvor, C. / Robert, A. / Haeuw, J.F. / Goetsch, L. et al. | 2014
- 114
-
353 Protein expression for receptor activator of NFkB (RANK) and its ligand (RANKL) in non-small cell lung cancer (NSCLC)D'Arcangelo, M. / Ekman, S. / Dougall, W. / Branstetter, D. / Bergqvist, M. / Liv, P. / Chan, D. / Botling, J. / Hirsch, F. et al. | 2014
- 114
-
352 UNC2025, a novel small molecule MerTK and Flt3 tyrosine kinase inhibitor, has therapeutic activity and promotes sensitivity to chemotherapy in animal models of acute leukemiaGraham, D. / DeRyckere, D. / Wang, X. / Hill, A.A. / Zhang, W. / Frye, S.V. / Earp, H.S. et al. | 2014
- 114
-
354 PCR-based assay for BRAFV600 mutation analysis in ctDNA: clinical results from plasma and serum samplesGonzalez-Cao, M. / de las Casas, C.M. / Molina-Vila, M.A. / de Mattos-Arruda, L. / Manzano, J.L. / Munoz, E. / Cortes, J. / Berros, J.P. / Sanmamed, M. et al. | 2014
- 115
-
358 Knockdown of beta-catenin with dicer-substrate siRNAs down-regulates Wntbeta-catenin pathway signalingPursell, N. / Zhou, W. / Diwanji, R. / Holmes, B. / Avitahl-Curtis, N. / Dutta, C. / Dudek, H. / Ganesh, S. / Abrams, M. et al. | 2014
- 115
-
356 Discovery of novel pyrido[2,3-b]pyrazine as fibroblast growth factor receptor (FGFR-1, 2, 3 & 4) kinase inhibitors with nanomolar affinityAngibaud, P. / Querolle, O. / Berdini, V. / Saxty, G. / Cleasby, A. / Colombel, H. / Csoka, I. / Gilissen, R. / King, P. et al. | 2014
- 115
-
357 Multi-color flow cytometry immunophenotyping for detection of CSC in NSCLCMartinez-Romero, A. / Pardo, J.M. / Tejedor, S. / Farinas, S.C. / Lucas, R. / Figueroa, S. / Jantus-Lewintre, E. / Camps, C. / Farras, R. et al. | 2014
- 115
-
355 Altiratinib (DCC-2701): a balanced inhibitor of MET, TIE2, and VEGFR2 kinases that exhibits broad anti-tumor and anti-angiogenic activitiesFlynn, D. / Smith, B.D. / Leary, C.B. / Kaufman, M.D. / Turner, B.A. / Hood, M.M. / Lu, W.P. / Rutkoski, T.J. / Samarakoon, T. et al. | 2014
- 116
-
359 Correlation of tumour-associated macrophage, but not tumour-infiltrating lymphocyte, levels with progression-free survival in patients with metastatic renal cell carcinoma treated with axitinibWilliams, J.A. / Martini, J.F. / Escudier, B. / Rini, B.I. / Motzer, R.J. / Tarazi, J. / Li, S. / English, P.A. et al. | 2014
- 116
-
360 Tumor suppressive microRNA-192 as a prognostic factor for recurrence of surgically resected non-small cell lung cancerHong, J.H. / Roh, K.S. / Jeon, E.K. / Kang, J.H. / Suh, S.S. / Lee, S.C. et al. | 2014
- 116
-
361 Nanoformulations of the PARP inhibitors olaparib and BMN 673 for cancer nanotherapySridhar, S. / Tangutoori, S. / Baldwin, P. et al. | 2014
- 117
-
363 Cytosolic p21 is a pharmacodynamic marker of CHEK1 and IKK inhibition in ovarian cancer cellsKim, M. / Min, D.J. / Wright, G. / Annunziata, C. et al. | 2014
- 117
-
362 Phenotypic plasticity in epithelial progenitors and mesenchymal carcinoma is regulated by Axl signalingEngelsen, A. / Wnup-Lipinska, K. / Tiron, C. / Pelissier, F. / Jokela, T. / Haaland, G. / Gausdal, G. / Sandal, T. / Frink, R. et al. | 2014
- 117
-
364 First-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAFNRAS-mutant melanomaMiddleton, M. / Rasco, D.W. / Olszanski, A.J. / Corrie, P. / Lorigan, P. / Plummer, R. / Larkin, J. / Pavlick, A. / Zhou, X. et al. | 2014
- 118
-
367 Induction of apoptosis and inhibition of angiogenesis by novel fusion protein - AD-O54.9 as a new preclinical strategy in cancer treatmentRozga, P. / Zerek, B. / Pieczykolan, A. / Galazka, M. / Bukato, K. / Pawlak, S. / Szymanik, M. / Jaworski, A. / Teska-Kaminska, M. et al. | 2014
- 118
-
365 Pim-1 kinase: Validated as a therapeutic cancer target for MYC-driven tumoursRenner, O. / Cecilia, Y. / de Miguel, M.C.R. / Peregrina, S. / Garcia-Serelde, B. / Albarran, M.I. / Cebria, A. / Cebrian, D. / Ramos-Lima, F. et al. | 2014
- 118
-
368 NP137, the first humanized monoclonal antibody directed against netrin-1, exhibits antitumor activity by inducing dependence receptors-mediated cell deathDelcros, J.G. / Ducarouge, B. / Abes, R. / Goldschneider, D. / Gibert, B. / Blachier, J.G. / Neves, D. / Mehlen, P. / Bernet, A. et al. | 2014
- 118
-
366 Targeting colorectal and pancreatic cancer stem cells with the LGR5 monoclonal antibody BNC101Chu, P. / Shojaei, F. / Smith, K. / Norton, J. / Walsh, C. / Iglesias, J. / Reyes, C. et al. | 2014
- 119
-
371 Selective targeting of head and neck cancer cells by perturbing reactive oxygen species homeostasisKwon, M. / Kim, J.W. / Kim, E.H. / Park, J.Y. / Kim, S.Y. / Roh, J.L. et al. | 2014
- 119
-
369 Diagnosis and molecular targeting for individualized treatment of patients with pre-neoplastic lesions and locally advanced cervical cancerMoreno-Acosta, P.M.A. / Romero-Rojas, A.R.R.A. / Salgado, A.H.S.A.H. / Mayorga, D.M.D. / Morales, N.M.N. / Acosta, J.A.J. / Gamboa, O.G.O. / Magne, N.M.N. / Molano, M.M.M. et al. | 2014
- 119
-
370 Discovery of the genes that underpin the transition to malignant phenotype of breast tissues in a highly consanguineous regionGupta, I. / Shanmuganathan, S. / Ouhtit, A. et al. | 2014
- 120
-
375 MER as a novel therapeutic target in colorectal cancerWong, K. / Tan, A.C. / Pitts, T. / Klauck, P. / Earp, S. / Frye, S. / Wang, X. / Graham, D.K. / Eckhardt, S.G. et al. | 2014
- 120
-
373 AKT2 gene amplification is a marker for sensitivity to allosteric but not ATP-competitive AKT inhibitorsAbe, T. / Ichikawa, K. / Fujita, R. / Okada, M. / Tanaka, K. / Ohkubo, M. / Yonekura, K. / Shimomura, T. / Utsugi, T. et al. | 2014
- 120
-
374 Neuregulin 1 (NRG1) expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor modelsMeetze, K. / Vincent, S. / Tyler, S. / Mazsa, E. / Delpero, A. / Bottega, S. / McIntosh, D. / Gyuris, J. / Weng, Z. et al. | 2014
- 120
-
372 Specific inhibition of hTERT expression by targeting common promoter mutations which cause quadruplex DNA instabilityMiller, D. / Sokolova, A. / Thomas, S. / Rezzoug, F. / Chaires, J. / Dean, W. / Buscaglia, R. / Trent, J. et al. | 2014
- 121
-
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanomaDel Vecchio, M. / Di Guardo, L. / Ascierto, P. A. / Grimaldi, A. M. / Sileni, V. C. / Pigozzo, J. / Ferraresi, V. / Nuzzo, C. / Rinaldi, G. / Testori, A. et al. | 2014
- 121
-
378 A first-in-human (FIH) safety and pharmacological study of SAR405838, a novel HDM2 antagonist, in patients with solid malignanciesde Weger, V. / Lolkema, M.P. / Dickson, M. / Le Cesne, A. / Wagner, A. / Merqui-Roelvink, M. / Varga, A. / Tap, W. / Schwartz, G. et al. | 2014
- 121
-
376 Tumor-targeting Salmonella typhimurium A1-R enhances gemcitabine-bevacizumab efficacy on a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse modelHiroshima, Y. / Zhao, M. / Katz, M.H.G. / Fleming, J.B. / Sato, S. / Murakami, T. / Yamamoto, M. / Uehara, F. / Miwa, S. et al. | 2014
- 121
-
377 Plucked hair as a platform for monitoring pharmacodynamic and mechanistic consequences of clinical exposure to the Wntbeta-catenin inhibitor PRI-724Miele, G. / Reed, B. / Harrison, E. / Mefo, T. / Read, J. / Senba, T. / Odagami, T. et al. | 2014
- 122
-
379 Identification and rational in silico-based targeting of a novel mediator of metastatic breast cancerClarkson, R. / Soukupova, J. / Wakefield, A. / Turnham, D. / Yang, W. / Bordoni, C. / Westwell, A. / Brancale, A. et al. | 2014
- 122
-
381 Efficacy of specific FGFR inhibitors against gatekeeper resistance mutations and shared mechanism of cell death in FGFR2-dependent endometrial cancer cell linesPacker, L. / Byron, S. / Stehbens, S. / Loch, D. / Dehkhoda, F. / Stephenson, S. / Pollock, P. et al. | 2014
- 122
-
382 Phase Ib study of oral dual-PI3KmTOR inhibitor GDC-0980 in combination with capecitabine and mFOLFOX6 + bevacizumab in patients with advanced solid tumors and colorectal cancerRosen, L. / Goldman, J. / Hubbard, J.M. / Roos, M. / Capdevila, J. / Maynes, J. / Lin, W. / O'Keeffe, B. / Lackner, M. et al. | 2014
- 122
-
380 Induction of apoptosis with a novel dual cIAP1XIAP antagonist in models of melanomaWard, G. / Chessari, G. / Johnson, C.N. / Lewis, J. / Rich, S. / Thompson, N. et al. | 2014
- 123
-
384 REDX04988, a novel dual B-RAFC-RAF inhibitor and a potential therapeutic for BRAF-mutant colorectal cancerRainard, J. / Testar, R. / Poonawala, R. / Mason, H. / Smith, P. / Brooke, H. / Huart, V. / Frith, S. / Ahmet, J. et al. | 2014
- 123
-
385 Noninvasive monitoring of acquired EGFR-T790M mutation and discovery of its heterogeneity in patients with advanced NSCLC treated with EGFR-TKIYe, X. / Zheng, D. / Zhang, M.Z. / Sun, Y. / Wang, J.Y. / Ni, J. / Zhang, H.P. / Zhang, L. / Luo, J. et al. | 2014
- 123
-
383 Identification of potent and selective tankyrase 12 inhibitors with activity in a subset of APC mutant colorectal cancerGuichard, S.M. / Zhang, Y. / Ferguson, D. / Mazzola, A. / Wang, H. / Bao, L. / Grosskurth, S. / Johannes, J. / Wagoner, M. et al. | 2014
- 124
-
388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumorsCardnell, R.J. / Behrens, C. / Diao, L. / Fan, Y. / Tang, X. / Minna, J.D. / Mills, G.B. / Heymach, J.V. / Wistuba, I.I. et al. | 2014
- 124
-
387 Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor modelsMerchant, M. / Chan, J. / Orr, C. / Cheng, J. / Wang, X. / Hunsaker, T. / Wagle, M.C. / Huang, S.A. / Tremayne, J. et al. | 2014
- 124
-
386 PI3K and MEK inhibitor combination toxicities and relative dose intensity: Vall d'Hebron experienceAzaro, A. / Marino, D. / Garrido-Castro, A. / Cruz, C. / Alsina, M. / Perez, J. / Dienstmann, R. / Argiles, G. / Hierro, C. et al. | 2014
- 125
-
391 LOXO-101, a pan TRK inhibitor, for the treatment of TRK-driven cancersWinski, S. / Baer, B. / Hartley, D. / Rhodes, S. / Wallace, R. / Smith, S. / Nanda, N. / Kunkle, L. / Lee, P. et al. | 2014
- 125
-
389 A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumorsPapadopoulos, K. / Tolcher, A. / Kittaneh, M. / Patniak, A. / Rasco, D. / Chambers, G. / Newth, G. / Savage, R. / Hall, T. et al. | 2014
- 125
-
392 Using modelling & simulation to integrate mouse PK-PD-efficacy with preliminary human PK data to inform the Phase II doses and schedule for the experimental c-Met inhibitor AZD6094 (Volitinib)Jones, R. / Cheung, A. / Coleman, T. / Ballard, P. / D'Cruz, C. / Schuller, A. / Frigault, M. / Gu, Y. / Sai, Y. et al. | 2014
- 125
-
390 Inhibitors of EZH2 act synergistically with type 1 interferon to induce a potent interferon-stimulated gene response, triggering apoptosis in diffuse large B-cell lymphomaBradley, B. / Zhao, F. / Yuan, C.C. / Balasubramanian, S. / Iyer, P. / Hatton, C. / Bryant, B. / Normant, E. / Trojer, P. et al. | 2014
- 126
-
395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)Choueiri, T.K. / Escudier, B. / Pal, S.K. / Jonasch, E. / Heng, D. / Powles, T. / Arkenau, H.T. / Clark, E. / D'Cruz, C. et al. | 2014
- 126
-
393 Small modification of ceritinib enhances the activity against ALKPark, C.H. / Kang, C.H. / Jung, H.J. / Kim, H.R. / Lee, C.O. / Lee, H.K. / Choi, S.U. et al. | 2014
- 126
-
394 Sensitivity of acute myeloid leukemia cells to a urokinase-activated anthrax lethal toxin (PrAgU2lf) is dependent on uPAR expression and phospho-MEK12 levelsBekdash, A. / Liu, S.H. / Leppla, S.H. / Frankel, A.E. / Abi-Habib, R. et al. | 2014
- 127
-
396 Gastrointestinal stromal tumor associated with neurofibromatosis type ITakahashi, T. / Nishida, T. / Nakatsuka, R. / Kaneda, M. / Hirota, S. / Miyazaki, Y. / Kurokawa, Y. / Yamasaki, M. / Miyata, H. et al. | 2014
- 127
-
398 TAS-119 a selective inhibitor of Aurora A kinase, potentiates taxane therapy in breast and lung cancer modelsNakatsuru, Y. / Hashimoto, A. / Sootome, H. / Ito, K. / Sakuragi, M. / Miura, A. / Oda, N. / Hirai, H. / Utsugi, T. et al. | 2014
- 127
-
397 Characterization of molecular targets of therapy in Non-Small Cell Lung Cancer (NSCLC) utilizing a liquid biopsyGreene, S. / Lu, D. / Krupa, R. / Harvey, M. / Louw, J. / Jendrisak, A. / Bales, N. / Marrinucci, D. / Gray, J. et al. | 2014
- 128
-
Primary cardiac sarcomas: A retrospective study of the French Sarcoma GroupIsambert, N. / Ray-Coquard, I. / Italiano, A. / Rios, M. / Kerbrat, P. / Gauthier, M. / Blouet, A. / Chaigneau, L. / Duffaud, F. / Piperno-Neumann, S. et al. | 2014
- 128
-
400 Optimization of novel pyrido[2,3-b]pyrazine based small molecule fibroblast growth factor receptor 1, 2, 3 & 4 (FGFR) inhibitors into a potential clinical candidateAngibaud, P. / Querolle, O. / Berdini, V. / Saxty, G. / Cleasby, A. / Colombel, H. / Csoka, I. / Esser, N. / Gilissen, R. et al. | 2014
- 128
-
401 TAS-121, a highly potent and mutant-specific EGFR inhibitor, overcomes T790M-acquired resistance with promising antitumor activity through specific inhibition of mutant EGFR signalingKato, M. / Miyadera, K. / Ito, K. / Aoyagi, Y. / Hashimoto, A. / Yonekura, K. / Iwasawa, Y. / Utsugi, T. et al. | 2014
- 128
-
402 Characterization of the oncogenic properties of mutant isocitrate dehydrogenase 1 (IDH1R132H) in human primary cellsBarradas, M. / Diezma, L. / Perez-Ferreiro, C.M. / Cerezo, A. / Lospitao, E. / Peregrina, S. / Jimenez, S. / Brooks, N.A. / Torres, R. et al. | 2014
- 128
-
399 Rho-GTPase, RAC1 and Cdc42 mediates Wnt-beta-catenin signals for metastasis associated phenotypes in TNBC: A proof of concept studyDey, N. / De, P. / Leyland-Jones, B. et al. | 2014
- 129
-
404 Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lungCavazzoni, A. / Bonelli, M. / Saccani, F. / La Monica, S. / Galetti, M. / Caffarra, C. / Cretella, D. / Fumarola, C. / Alfieri, R. et al. | 2014
- 129
-
403 A novel dielectrophoretic microwell array system for detection and single cell analysis of circulating tumor cells from breast cancer patientsSawada, T. / Morimoto, A. / Mogami, T. / Iijima, K. / Akiyama, Y. / Katayama, K. / Futami, T. / Yunokawa, M. / Tamura, K. et al. | 2014
- 129
-
405 Aurora kinases A and B are required for KRAS-induced lung cell oncogenicitySantos, E.O.O.d. / Aoki, M.N. / Levantini, E. / Basseres, D.S. et al. | 2014
- 130
-
408 A potent and selective small molecule inhibitor of MCL-1 sensitizes DLBCL cell lines to the BCL-2 selective inhibitor ABT-199Phillips, D.C. / Xiao, Y. / Lam, L. / Litinovic, E. / Roberts-Rapp, L. / Souers, A.J. / Leverson, J.D. et al. | 2014
- 130
-
407 Structural basis for inhibition of ligand-dependent and -independent ErbB3 activation by KTN3379Alvarado, D. / Lee, S. / Greenlee, E. / Ligon, G.F. / Lillquist, J.S. / Natoli, E.J. / Amick, J. / Hadari, Y. / Schlessinger, J. et al. | 2014
- 130
-
409 Transcription factor activating protein 2 beta (TFAP2B) mediates neuronal differentiation in neuroblastomaIkram, F. / Ackermann, S. / Roels, F. / Volland, R. / Hero, B. / Hertwig, F. / Kocak, H. / Dreidax, D. / Henrich, K.O. et al. | 2014
- 130
-
406 Aflibercept (Zaltrap) directly attenuates the migration and invasion of colorectal cancer cellsBouygues, A. / Mesange, P. / Ayadi, M. / Poindessous, V. / Chiron, M. / Dochy, E. / Andre, T. / de Gramont, A. / Larsen, A.K. et al. | 2014
- 131
-
411 Druggability of p16 deleted pediatric leukemia: The novel cell line POETIC3 identifies potential agents and drug combinations for mechanism based targeted therapeuticsReimer, J. / Kovulchuk, A. / Ruan, Y. / Shah, R. / Jayanthan, A. / Perinpanayagam, M. / Truong, T. / Auer-Grzesiak, I. / Luider, J. et al. | 2014
- 131
-
410 Pediatric Preclinical Testing Program (PPTP) Evaluation of the p53-MDM2 Antagonist MK-8242Smith, M. / Kang, M. / Reynolds, P. / Lock, R. / Carol, H. / Gorlick, R. / Kolb, A. / Maris, J. / Keir, S. et al. | 2014
- 131
-
412 The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testingHoughton, P. / Lock, R. / Carol, H. / Gorlick, R. / Kolb, A. / Maris, J. / Keir, S. / Wu, J. / Kang, M. et al. | 2014
- 132
-
415 Comprehensive next generation sequencing of solid tumors from 669 adolescents and young adults reveals a distinct spectrum of targetable genomic alterationsMorosini, D. / Wang, K. / Wagner, K. / Gershenhorn, B. / Yelensky, R. / Lipson, D. / Chmielecki, J. / Ali, S.M. / Ross, J.S. et al. | 2014
- 132
-
413 Next-generation sequencing identifies the mechanism of tumourigenesis caused by loss of SMARCB1 in malignant rhabdoid tumoursFinetti, M.A. / Selby, M. / del Carpio Pons, A. / Wood, J. / Skalkoyannis, B. / Smith, A. / Crosier, S. / Bailey, S. / Clifford, S. et al. | 2014
- 132
-
414 Genomic profiling using a clinical next generation sequencing (NGS) assay reveals genomic alterations to guide targeted therapy in advanced neuroblastoma patientsAli, S. / Sanford, E.M. / Hawryluk, M.J. / Chmielecki, J. / Wang, K. / Palmer, G.A. / Palma, N.A. / Morosini, D. / Erlich, R. et al. | 2014
- 133
-
416 Results of phase I study of bolus 5-fluorouracil in children and young adults with recurrent ependymomaWright, K.D. / Turner, D.C. / Haddock, K.M. / Jacus, M.O. / Harstead, K.E. / Throm, S.L. / Daryani, V.M. / Robinson, G.W. / Armstrong, G.T. et al. | 2014
- 133
-
418 Population pharmacokinetics of intravenous bolus 5-fluorouracil in a phase I trial for children and young adults with recurrent ependymomaTurner, D.C. / Haddock, K.M. / Jacus, M.O. / Harstead, K.E. / Throm, S.L. / Daryani, V.M. / Stewart, C.F. / Wright, K.D. et al. | 2014
- 133
-
417 Evaluating the activity of the p53-MDM2 inhibitor NDD0005 in Ewing sarcomaPecqueur, J. / Vormoor, B. / Zhao, Y. / Newell, H. et al. | 2014
- 134
-
419 Targeted inhibition of casein kinase II (CK2) produces a strong therapeutic effect in pediatric leukemiaDovat, S. / Song, C. / Gowda, C. / Payne, K.J. et al. | 2014
- 134
-
420 Analysis of genomic alterations in Ewing sarcoma (German cohort) reveals cooperating mutations and novel therapy targetsRichter, G.H.S. / Agelopoulos, K. / Schmidt, E. / von Heyking, K. / Moser, B. / Klein, H.U. / Kontny, U. / Dugas, M. / Poos, K. et al. | 2014
- 135
-
422 CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in pre-clinical models of neuroblastomaHaber, M. / Murray, J. / Gamble, L. / Carnegie-Clark, A. / Webber, H. / Ruhle, M. / Carter, D. / Oberthur, A. / Fischer, M. et al. | 2014
- 135
-
423 RNA helicase A is essential for 1p36 gene KIF1B@b tumor suppression in neuroblastomasChen, Z.X. / Wallis, K. / Fell, S.M. / Sobrado, V.R. / Hemmer, M.C. / Ramskold, D. / Choo, Z. / Hellman, U. / Sandberg, R. et al. | 2014
- 135
-
421 Molecular profiling for factors predicting sensitivity or resistance to therapy in relapsed child cancerSaletta, F. / Wadham, C. / Byrne, J. / Ziegler, D. / McCowage, G. / Haber, M. / Marshall, G. / Norris, M. et al. | 2014
- 136
-
425 Evaluation of drug reactions to anti-neoplastic agents in Phase I clinical trialsBupathi, M. / Hajjar, J. / Hess, K. / Bean, S. / Karp, D. / Meric-Bernstam, F. / Naing, A. et al. | 2014
- 136
-
426 Serum levels of CCL22 and CCL25 might predict skin rash induction the commonest adverse event by bendamustine in the treatment of malignant lymphomaTerni, Y. / Kuniyoshi, R. / Mishima, Y. / Hatake, K. et al. | 2014
- 136
-
424 Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916Prell, R. / Halpern, W. / Beyer, J. / Tarrant, J. / Sukumaran, S. / Huseni, M. / Kaiser, R. / Wilkins, D. / Karanth, S. et al. | 2014
- 136
-
427 Hematotoxicity potential of new drug candidates measured in hematopoietic progenitors in bone marrow samplesBallesteros, J. / Primo, D. / Hernandez, P. / Robles, A. / Espinosa, A.B. / Arroyo, E. / Garcia-Navas, V. / Sanchez-Fenoy, J. / Jimenez, M. et al. | 2014
- 137
-
Identification of brain tumour initiating cells using the stem cell marker aldehyde dehydrogenaseChoi, S. A. / Lee, J. Y. / Phi, J. H. / Wang, K. C. / Park, C. K. / Park, S. H. / Kim, S. K. et al. | 2014
- 141
-
429 Development of extracellular signal-regulated kinase 5 (ERK5) inhibitors for anti-cancer therapyMyers, S. / Martin, N. / Bawn, R. / Blackburn, T. / Barrett, L. / Reuillon, T. / Golding, B. / Griffin, R. / Hammonds, T. et al. | 2014
- 141
-
430 Design and structure-activity relationships of highly potent and bioavailable imidazolinone FASN KR domain inhibitorsBignan, G. / Alexander, R. / Bischoff, J. / Connolly, P. / Cummings, M. / de Breucker, S. / Esser, N. / Fraiponts, E. / Gilissen, R. et al. | 2014
- 141
-
428 Clinical acquired resistance to combined RAFEGFR or RAFMEK inhibition in BRAF mutant colorectal cancer (CRC) patients through MAPK pathway alterationsCorcoran, R. / Coffee, E.M. / van Allen, E. / Ahronian, L.G. / Wagle, N. / Kwak, E.L. / Faris, J.E. / Iafrate, A.J. / Garraway, L.A. et al. | 2014
- 142
-
433 Genomic predictors of therapeutic sensitivity to TAS-119, a selective inhibitor of Aurora-A kinaseSootome, H. / Fujita, N. / Miura, A. / Suzuki, T. / Fukushima, H. / Mizuarai, S. / Hirai, H. / Utsugi, T. et al. | 2014
- 142
-
431 Real-time pharmacokinetic (PK) results from an ongoing randomized, parallel-dose phase 1 study of onapristone in patients (pts) with progesterone receptor (PR)-expressing cancersLokiec, F. / Bonneterre, J. / Italiano, A. / Varga, A. / Campone, M. / LeSimple, T. / Leary, A. / Dieras, V. / Rezai, K. et al. | 2014
- 142
-
432 ODM-203, a novel, selective and balanced FGFR and VEGFR inhibitor with strong anti-tumor activity in FGFR- and VEGFR-dependent cancer modelsHolmstrom, T. / Moilanen, A. / Linnanen, T. / Wohlfahrt, G. / Karlsson, S. / Oksala, R. / Korjamo, T. / Bjorkman, M. / Samajadar, S. et al. | 2014
- 143
-
434 Bipolar androgen therapy for men with castration sensitive and castration resistant prostate cancer: Reversing resistance and maintaining sensitivity to androgen ablative therapiesDenmeade, S.R. / Antonarakis, E.S. / Eisenberger, M.A. / Carducci, M.A. / Wang, H. / Paller, C.J. / Isaacs, J.T. / Schweizer, M.T. et al. | 2014
- 143
-
436 Monitoring activity of RXDX-101 in Phase 12 patients using a pharmacodynamic assay for TrkA activationMurphy, D. / Ely, H. / Patel, R. / Wei, G. / Diliberto, A. / Shoemaker, R. / Christiansen, J. et al. | 2014
- 143
-
435 A pan-cancer tumor-derived epithelial-to-mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMTMak, M.P. / Tong, P. / Diao, L. / Ng, P.K.S. / Fan, Y. / Cardnell, R.J. / Gibbons, D.L. / William, W.N. / Heymach, J.V. et al. | 2014
- 144
-
438 MM-131: A bispecific antibody that inhibits c-Met signaling through avid binding to the EpCAM tumor antigenHarms, B.D. / Lugovskoy, A. / Abu-Yousif, A. / Fulgham, A. / Geddie, M. / Su, S.V. / Kohli, N. / Johnson, B. / Masson, K. et al. | 2014
- 144
-
440 Phenotypic alteration in a highly metastatic variant of the MDA-MB-231 cell line: role of Annexin A1Tu, Y. / Fietz, E. / Cameron, J. / Stewart, A. et al. | 2014
- 144
-
439 PI3KmTOR inhibitor VS-5584 targets cancer stem cells and prevents tumor regrowth after chemotherapy in preclinical models of small cell lung cancerKolev, V. / Padval, M. / Wright, Q. / Ricono, J. / Weaver, D. / Pachter, J. / Xu, Q. et al. | 2014
- 144
-
437 PIM kinase inhibitor AZD1208 sensitises SCLC to BH3 mimetic AZD4320Sloane, R. / Bola, B. / Lancashire, M. / Hodgkinson, C. / Morrow, C. / Simpson, K. / Dive, C. et al. | 2014
- 145
-
442 Targeting urokinase plasminogen activator for radioimmunotherapy using an antagonistic internalizing human antibodyLeBeau, A. / VanBrocklin, H.F. et al. | 2014
- 145
-
443 Notch3-targeted antibody drug conjugates have superior preclinical efficacy to Notch signaling inhibitorsGeles, K.G. / Gao, Y. / Sridharan, L. / Giannakou, A. / Yamin, T.T. / Golas, J. / Charati, M. / Lucas, J. / Wang, K. et al. | 2014
- 145
-
441 The role of methylation in metastasis of oral squamous cell carcinoma: understanding the OSCC methylomeClausen, M. / Melchers, L.J. / de Meyer, T. / Denil, S. / Criekinge, W. / Wisman, G.B. / Roodenburg, J.L.N. / Schuuring, E. et al. | 2014
- 146
-
446 The cancer stem cell inhibitors VS-6063 (defactinib) and VS-5584 exhibit synergistic anticancer activity in preclinical models of mesotheliomaXu, Q. / Tam, W.F. / Vidal, C.M. / Kolev, V.N. / Kadariya, Y. / Menges, C.W. / Testa, J.R. / Pachter, J.A. et al. | 2014
- 146
-
445 MEK inhibition enhances gemcitabine efficacy by increasing MDM2-mediated ubiquitination and degradation of RRM1Vena, F. / Li Causi, E. / Hagemann, T. / Hartley, J.A. / Goodstal, S. / Hochhauser, D. et al. | 2014
- 146
-
444 Debio 1143 in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and platinum-refractory epithelial ovarian cancer (EOC). Preliminary results of a Phase I dose-escalation studyLe Tourneau, C. / Ray-Coquard, I. / Isambert, N. / Gomez-Roca, C.A. / Cassier, P. / Sablin, M.P. / Ruits, E. / Gavillet, B. / Zanna, C. et al. | 2014
- 147
-
449 Cytokine induces MIR-424 expression and modulates SOCS2STAT5 signaling pathway in oral cancerShiah, S.G. / Peng, H.Y. / Jin, S.L.C. / Chang, J.Y. / Kuo, C.C. et al. | 2014
- 147
-
447 Novel, quantitative in vivo shRNA screening approach identifies new molecular targets to block cancer metastasisWilletts, L. / Paproski, R. et al. | 2014
- 147
-
450 Precise gene editing of mutant NRAS using CRISPR to determine sensitivity to trametinibHose, C. / Fer, N.D. / Burkett, M. / Connelly, J. / Harris, E. / Lih, J. / Williams, M. / Evans, D. / Silvers, T. et al. | 2014
- 147
-
448 Exposure to EGFR inhibitors influences release of extracellular vesicles by tumor cellsvan der Meel, R. / van Dommelen, S.M. / de Corte, P. / Coimbra, M. / van Solinge, W.W. / Vader, P. / Schiffelers, R.M. et al. | 2014
- 148
-
451 Correlative and updated clinical endpoint analysis of a multicenter phase II trial of selumetinib (AZD6244) plus erlotinib in chemotherapy-refractory advanced pancreatic adenocarcinoma (PDAC)Ko, A.H. / Tempero, A.H. / Bekaii-Saab, T.B. / Kuhn, P. / Courtin, R. / Ziyeh, S. / Tahiri, S. / Kelley, R.K. / Dito, E. et al. | 2014
- 148
-
452 eIF2alpha phosphorylation determines the adaptation of tuberous sclerosis complex mutant cells to stress and their response to anti-tumor therapiesKoromilas, A. / Tenkerian, C. / Krishnamoorthy, J. / Kamindla, R. / Kazimierczak, U. / Wang, S. et al. | 2014
- 148
-
453 Plasma metabolomic signature of novel signal transduction inhibitors from preclinical identification to clinical validationAng, J.E. / Pandher, R. / Asad, Y. / Skene, D.J. / Workman, P. / Eccles, S. / de Bono, J. / Kaye, S. / Banerji, U. et al. | 2014
- 149
-
456 SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibitionBuonamici, S. / Lim, K. / Feala, J. / Darman, R. / Myint, K. / Park, E. / Aird, D. / Chan, B. / Fekkes, P. et al. | 2014
- 149
-
454 Monitoring therapy response and resistance mutations in circulating RNA and DNA of plasma from patients with malignant melanomaEnderle, D. / Brinkmann, K. / Koestler, T. / Bentink, S. / Flaherty, K.T. / Skog, J. / Noerholm, M. et al. | 2014
- 149
-
455 Role of MDM2 as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)Briest, F. / Grass, I. / Christen, F. / Lewens, F. / Freitag, H. / Kaemmerer, D. / Saenger, J. / Hummel, M. / Siegmund, B. et al. | 2014
- 150
-
457 Preclinical pharmacology of AZD5312, a generation 2.5 antisense oligonucletotide targeting the androgen receptor with differentiated activity from enzalutamideDavies, B.R. / Thomason, A. / Ellston, R. / Campbell, H. / D'Cruz, C. / Mazzola, A.M. / Zhou, T. / Schmidt, J. / Jo, M. et al. | 2014
- 150
-
460 Molecular biomarkers of inflammatory signature in melanomaEkmekcioglu, S. / Shin-Sim, M. / Tanese, K. / Prieto, V.G. / Hoon, D.S. / Grimm, E.A. et al. | 2014
- 150
-
Quantitative and qualitative analysis of study-related patient information sheets in randomised neuro-oncology phase III-trialsReinert, C. / Kremmler, L. / Burock, S. / Bogdahn, U. / Wick, W. / Gleiter, C. H. / Koller, M. / Hau, P. et al. | 2014
- 150
-
458 Combinational genome and proteome survey of therapeutic targets of hepatocellular carcinomaYamada, T. et al. | 2014
- 150
-
459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigationMortensen, D.S. / Fultz, K.E. / Xu, W. / Tsuji, T. / Hickman, M. / Abbasian, M. / Khambatta, G. / Cathers, B. / Worland, P. et al. | 2014
- 151
-
461 A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF mutated advanced malignanciesHaraldsdottir, S. / Janku, F. / Timmers, C. / Geyer, S. / Schaaf, L.J. / Sexton, J. / Thurmond, J. / Velez-Bravo, V. / Stepanek, V.M. et al. | 2014
- 151
-
462 Clinical sequencing of cancer in real-time by digital sequencing of cell-free DNA for tailoring targeted therapy in refractory cancer patientsTalasaz, A. / Mortimer, S. / Schiller, B.J. / Mei, G. / Huang, S. / Hoon, D.S.B. / Eltoukhy, H. et al. | 2014
- 151
-
464 Influence of warm and cold ischemia on molecular patterns in clinical biospecimenUnger, F.T. / Lange, N. / Uhlig, P.C. / Juhl, H. / David, K.A. et al. | 2014
- 151
-
463 PTPN11 is a central node in intrinsic and acquired resistance to targeted cancer drugsPrahallad, A. et al. | 2014
- 152
-
467 Two in one - Delivery of apoptotic signal into cancer cells by new class of TRAIL derived, fusion proteinPawlak, S.D. / Zerek, B.M. / Rozga, P.K. / Bukato, K. / Szymanik, M. / Teska-Kaminska, M. / Pieczykolan, A. / Jaworski, A. / Galazka, M. et al. | 2014
- 152
-
466 IGF2 drives IGF oncogenic signaling in HCC and emerges as a potential target for therapiesQuetglas, I.M. / Pinyol, R. / Dauch, D. / Portela, A. / Villanueva, A. / Peix, J. / Higuera, M. / Moeini, A. / Zucman-Rossi, J. et al. | 2014
- 152
-
465 Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)Kapoun, A. / O'Reilly, E. / Cohn, A. / Bendell, J.C. / Smith, L. / Strickler, J.H. / Gluck, W. / Liu, Y.W. / Wallace, B. et al. | 2014
- 153
-
469 OTX015, a novel BET-bromodomain (BET-BRD) inhibitor, is a promising anticancer agent for human glioblastomaOuafik, L. / Berenguer, C. / Cayol, M. / Astorgues-Xerri, L. / Bekradda, M. / Odore, E. / Rezai, K. / Riveiro, M.E. / Cvitkovic, E. et al. | 2014